Compounds for binding to the platelet specific glycoprotein IIb/IIIa and their use for imaging of thrombi

Abstract

The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (PET) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body. More particularly, the invention relates to small nonpeptide, high-affinity, specific-binding glycoprotein IIb/IIIa antagonists for imaging of thrombi.

Claims

1. Compounds of Formula I: ##STR00331## wherein R.sup.1 is hydrogen or an amine-protecting group; R.sup.2 is hydrogen or a carboxyl-protecting group; wherein at least one of R.sup.1 and R.sup.2 is not H; R.sup.3 is selected from the group consisting of H, F, CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN and NO.sub.2; R.sup.4 is selected from the group consisting of OH, Halogen, —NO.sub.2, —N.sup.+(Me).sub.3(W.sup.−), —I.sup.+R.sup.11(W.sup.−)—O(CH.sub.2).sub.n-LG, —(OCH.sub.2CH.sub.2).sub.m-LG, Q, —OCH.sub.2-Q; —CH.sub.2—CH.sub.2-Q, —CH═CH-Q and —C≡C-Q; X is selected from CH or N; LG is a leaving group; R.sup.9 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.10 is (C.sub.1-C.sub.6)alkyl; R.sup.11 is selected from the group consisting of phenyl, (4-methyl)phenyl, (4-methoxy)phenyl, 2-furanyl and 2-thienyl; W.sup.− is selected from the group comprising CF.sub.3(S(O).sub.2O.sup.−, iodide anion, bromide anion and CF.sub.3C(O)O.sup.−; Q is a group ##STR00332## wherein * indicates the atom of connection of Q; R.sup.5 is selected from the group consisting of H, CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN and NO.sub.2; R.sup.6 is selected from the group consisting of OH, Halogen, —NO.sub.2, —N.sup.+(Me).sub.3(W.sup.−), —I.sup.+R.sup.11(W.sup.31), —O(CH.sub.2).sub.n-LG and —(OCH.sub.2CH.sub.2).sub.m-LG; n is 1-3; and m is 2-3; with the proviso that if R.sup.4 has the meaning of Halogen, —NO.sub.2, —N.sup.+(Me).sub.3(W.sup.−) or —I.sup.+R.sup.11(W.sup.−), R.sup.3 has the meaning of CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN or NO.sub.2 and with the proviso that if R.sup.6 has the meaning of Halogen, —NO.sub.2, —N.sup.+(Me).sub.3(W.sup.−) or —I.sup.+R.sup.11(W.sup.−), R.sup.5 has the meaning of CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN or NO.sub.2; including E and Z-isomers and diastereomers, mixtures thereof, and any pharmaceutically acceptable salt or complex thereof.

2. Compounds according to claim 1, wherein R.sup.1 is hydrogen or an amine-protecting group; R.sup.2 is hydrogen or a carboxyl-protecting group; wherein at least one of R.sup.1 and R.sup.2 is not H; R.sup.3 is H, F, CF.sub.3, CN or NO.sub.2; R.sup.4 is OH, Halogen, —N.sup.+(Me).sub.3(W.sup.−), —O(CH.sub.2).sub.n-LG, —(OCH.sub.2CH.sub.2).sub.m-LG, Q, —OCH.sub.2-Q; —CH.sub.2—CH.sub.2-Q, —CH═CH-Q or —C≡C-Q; X is CH or N; LG is a leaving group; W.sup.− is CF.sub.3(S(O).sub.2O.sup.−, a bromide anion or CF.sub.3C(O)O.sup.−; Q is a group ##STR00333## wherein * indicates the atom of connection of Q; R.sup.5 is H, CF.sub.3, CN or NO.sub.2; R.sup.6 is OH, Halogen, —N.sup.+(Me).sub.3(W.sup.−), —O(CH.sub.2).sub.n-LG and or —(OCH.sub.2CH.sub.2).sub.m-LG; n is 1-3; and m is 2-3; with the proviso that if R.sup.4 has the meaning of Halogen or —N.sup.+(Me).sub.3(W.sup.−), R.sup.3 has the meaning of CF.sub.3, CN or NO.sub.2 and with the proviso that if R.sup.6 has the meaning of Halogen or —N.sup.+(Me).sub.3(W.sup.−), R.sup.5 has the meaning of CF.sub.3, CN or NO.sub.2; including E and Z-isomers and diastereomers and mixtures thereof.

3. Compounds according to claim 1, wherein R.sup.1 is hydrogen or an amine-protecting group selected from the group consisting of tert-butyloxycarbonyl (BOC), carbobenzyloxy (Cbz) and 9-fluorenylmethyloxycarbonyl (FMOC); R.sup.2 is hydrogen or a carboxyl-protecting group selected from the group consisting of methyl, ethyl, propyl, tert-butyl, benzyl and p-methoxybenzyl; wherein at least one of R.sup.1 and R.sup.2 is not H; R.sup.3 is H, F, CF.sub.3, CN or NO.sub.2; R.sup.4 is OH, Halogen, —N.sup.+(Me).sub.3(W.sup.−), —O(CH.sub.2).sub.n-LG, —(OCH.sub.2CH.sub.2).sub.m-LG, Q, —OCH.sub.2-Q; —CH.sub.2—CH.sub.2-Q, —CH═CH-Q or —C≡C-Q; X is CH or N; LG is a leaving group selected from the group comprising methylsulfonyloxy and (4-methylphenyl) sulfonyloxy; W.sup.− is CF.sub.3(S(O).sub.2O.sup.−, a bromide anion or CF.sub.3C(O)O.sup.−; Q is a group ##STR00334## wherein * indicates the atom of connection of Q; R.sup.5 is H, CF.sub.3, CN or NO.sub.2; R.sup.6 is OH, Halogen, —N.sup.+(Me).sub.3(W.sup.−), —O(CH.sub.2).sub.n-LG or —(OCH.sub.2CH.sub.2).sub.m-LG; n is 1-3; and m is 2-3; with the proviso that if R.sup.4 has the meaning of Halogen or —N.sup.+(Me).sub.3(W.sup.−), R.sup.3 has the meaning of CF.sub.3, CN or NO.sub.2 and with the proviso that if R.sup.6 has the meaning of Halogen or —N.sup.+(Me).sub.3(W.sup.—), R.sup.5 has the meaning of CF.sub.3, CN or NO.sub.2; including E and Z-isomers and diastereomers and mixtures thereof.

4. Compounds according to claim 1, wherein R.sup.1 is tert-butyloxycarbonyl (BOC); R.sup.2 is methyl or tert-butyl; wherein at least one of R.sup.1 and R.sup.2 is not H; R.sup.3 is H; R.sup.4 is —O(CH.sub.2).sub.n-LG; X is N; LG is methylsulfonyloxy or (4-methylphenyl)sulfonyloxy; W.sup.− is CF.sub.3(S(O).sub.2O.sup.−, a bromide anion or CF.sub.3C(O)O.sup.−; Q is a group ##STR00335## wherein * indicates the atom of connection of Q; R.sup.5 is H, CF.sub.3, CN or NO.sub.2; R.sup.6 is OH, Halogen, —N.sup.+(Me).sub.3(W.sup.−), —O(CH.sub.2).sub.n-LG or —(OCH.sub.2CH.sub.2).sub.m-LG; n is 1-3; and m is 2-3; with the proviso that if R.sup.6 has the meaning of Halogen or —N.sup.+(Me).sub.3(W.sup.−), R.sup.5 has the meaning of CF.sub.3, CN or NO.sub.2; including E and Z-isomers and diastereomers and mixtures thereof.

5. Compounds of Formula I according to claim 1, selected from: tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat, tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}-ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate; tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-cyanophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl-4-{3-[(3R)-3-{[(1S)-1-{5-[(3-bromo-4-cyanobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[2-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-[3-((3R)-3-{[1-(4-hydroxyphenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({(1S)-1-[3-hydroxyphenyl]-3-methoxy-3-oxopropyl}carbamoyl)-piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(hydroxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[5-(3-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[5-(2-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1-(5-fluoro-4′-hydroxybiphenyl-3-yl)-3-methoxy-3-oxopropyl]-carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(4-hydroxyphenyl)-3-oxopropyl]-carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-hydroxypyridin-3-yl)-3-oxopropyl]-carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-(3-{(3R)-3-[(3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-(3-{(3R)-3-[(3-tert-butoxy-1-{5-[2-(4-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, and tert-butyl 4-(3-{(3R)-3-[(3-tert-butoxy-1-{5-[2-(3-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate.

6. A kit comprising a sealed vial containing a predetermined quantity of a compound selected from the compounds of Formula I according to claim 1, stereoisomers thereof and their mixtures, suitable salts of inorganic or organic bases and acids thereof, and hydrates, complexes, esters, amides, and solvates thereof.

7. Compounds of the formula I of claim 1, wherein: R.sup.9 is hydrogen or (C.sub.1-C.sub.4) alkyl; R.sup.10 is (C.sub.1-C.sub.4) alkyl; and R.sup.11 is selected from the group consisting of (4-methoxy)phenyl and 2-thienyl.

8. Compounds of the formula I of claim 1, wherein: R.sup.9 is hydrogen, methyl, ethyl or tert-butyl; R.sup.10 is methyl, ethyl or tert-butyl; and R.sup.11 is selected from the group consisting of (4-methoxy)phenyl and 2-thienyl.

9. Compounds of Formula II: ##STR00336## wherein R.sup.1 is hydrogen or an amine-protecting group; R.sup.2 is hydrogen or a carboxyl-protecting group; wherein at least one of R.sup.1 and R.sup.2 is not hydrogen; R.sup.3 is selected from the group consisting of H, F, CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN and NO.sub.2; R.sup.7 is selected from the group consisting of Y, —O(CH.sub.2).sub.n—Y, —(OCH.sub.2CH.sub.2).sub.m—Y, Z, —OCH.sub.2—Z; —CH.sub.2—CH.sub.2—Z, —CH═CH—Z and —C≡C—Z; X is selected from CH or N; Y is selected from .sup.18F or F; R.sup.9 is hydrogen or (C.sub.1-C.sub.6)alkyl; R.sup.10 is (C.sub.1-C.sub.6)alkyl; Z is a group ##STR00337## wherein * indicates the atom of connection of Z; R.sup.5 is selected from the group consisting of H, CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10,SO.sub.2R.sup.10, CN and NO.sub.2; R.sup.8 is selected from the group consisting of Y, —O(CH.sub.2).sub.n—Y and —(OCH.sub.2CH.sub.2).sub.m—Y; n is 1-3; and m is 2-3; with the proviso that if R.sup.7 has the meaning Y, R.sup.3 has the meaning of CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN or NO.sub.2 and with the proviso that if R.sup.8 has the meaning Y, R.sup.5 has the meaning of CF.sub.3, COR.sup.9, COOR.sup.10, SOR.sup.10, SO.sub.2R.sup.10, CN or NO.sub.2; including E and Z-isomers and diastereomers, mixtures thereof, and any pharmaceutically acceptable salt or complex thereof.

10. Compounds according to claim 9, wherein R.sup.1 is hydrogen or an amine-protecting group; R.sup.2 is hydrogen or a carboxyl-protecting group; wherein at least one of R.sup.1 and R.sup.2 is not hydrogen; R.sup.3 is H, F, CF.sub.3, CN or NO.sub.2; R.sup.7 is Y, —O(CH.sub.2).sub.n—Y, —(OCH.sub.2CH.sub.2).sub.m—Y, Z, —OCH.sub.2—Z; —CH.sub.2—CH.sub.2—Z, —CH═CH—Z or —C≡C—Z; X is CH or N; Y is .sup.18F or F; Z is a group ##STR00338## wherein * indicates the atom of connection of Z; R.sup.5 is H, CF.sub.3, CN or NO.sub.2; R.sup.8 is Y, —O(CH.sub.2).sub.n—Y or —(OCH.sub.2CH.sub.2).sub.m—Y; n is 1-3; and m is 2-3; with the proviso that if R.sup.7 has the meaning of Y, R.sup.3 has the meaning of CF.sub.3, CN or NO.sub.2 and with the proviso that if R.sup.8 has the meaning of Y, R.sup.5 has the meaning of CF.sub.3, CN or NO.sub.2; including E and Z-isomers and diastereomers and mixtures thereof.

11. Compounds according to claim 9, wherein R.sup.1 is hydrogen or an amine-protecting group selected from the group consisting of tert-butyloxycarbonyl (BOC), carbobenzyloxy (Cbz) and 9-fluorenylmethyloxycarbonyl (FMOC); R.sup.2 is hydrogen or a carboxyl-protecting group selected from the group consisting of methyl, ethyl, propyl, tert-butyl, benzyl and p-methoxybenzyl; wherein at least one of R.sup.1 and R.sup.2 is not hydrogen; R.sup.3 is H, F, CF.sub.3, CN or NO.sub.2; R.sup.7 is Y, —O(CH.sub.2).sub.n—Y, —(OCH.sub.2CH.sub.2).sub.m—Y, Z, —OCH.sub.2—Z; —CH.sub.2—CH.sub.2—Z, —CH═CH—Z or —C≡C—Z; X is N; Y is .sup.18F or F; Z is a group ##STR00339## wherein * indicates the atom of connection of Z; R.sup.5 is H, CF.sub.3, CN or NO.sub.2; R.sup.8 is Y, —O(CH.sub.2).sub.n—Y or —(OCH.sub.2CH.sub.2).sub.m—Y; n is 1-3; and m is 2-3; with the proviso that if R.sup.7 has the meaning of Y, R.sup.3 has the meaning of CF.sub.3, CN or NO.sub.2 and with the proviso that if R.sup.8 has the meaning of Y, R.sup.5 has the meaning of CF.sub.3, CN or NO.sub.2; including E and Z-isomers and diastereomers and mixtures thereof.

12. Compounds according to claim 9, wherein R.sup.1 is tert-butyloxycarbonyl (BOC); R.sup.2 is methyl or tert-butyl; R.sup.3 is H; R.sup.7 is —O(CH.sub.2).sub.n—Y; X is N; Y is .sup.18F or F; Z is a group ##STR00340## wherein * indicates the atom of connection of Z; R.sup.5 is H, CF.sub.3, CN or NO.sub.2; R.sup.8 is Y, —O(CH.sub.2).sub.n—Y or —(OCH.sub.2CH.sub.2).sub.m—Y; n is 1-3; and m is 2-3; with the proviso that if R.sup.8 has the meaning of Y, R.sup.5 has the meaning of CF.sub.3, CN or NO.sub.2; including E and Z-isomers and diastereomers and mixtures thereof.

13. Compounds of Formula II according to claim 9, selected from: 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-fluoroethoxy)phenyl]propanoic acid, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[4-(2-fluoroethoxy)phenyl]propanoic acid, tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(3-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}phenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[1-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid, tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid, tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid, tert-butyl 4-{3-[(3R)-3-({1-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]propanoic acid, tert-butyl 4-{3-[(3R)-3-({1-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]propanoic acid, tert-butyl 4-{3-[(3R)-3-({1-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]propanoic acid, tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(3-cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(4-cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-fluoroethoxy)phenyl]ethynyl}-pyridine-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]propanoic acid, tert-butyl 4-{3-[(3R)-3{[(1S)-3-tert-butoxy-1-({[4-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, (E/Z) tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-fluoroethoxy)phenyl]ethenyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{3-[2-[.sup.18F]fluoroethoxy]phenyl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (3S)-3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-{3-[2-[.sup.8F]fluoroethoxy]phenyl}propanoic acid, tert-butyl 4-{3-[(3R)-3-({1-[4-(2-[.sup.18F]fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}-carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{4-[2-[.sup.18F]fluoroethoxy]phenyl}propanoic acid, tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-[.sup.18F]fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(2-[.sup.18F]fluoroethoxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, (3S)-3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[2-[.sup.18F]fluoroethoxy]pyridin-3-yl}propanoic acid, tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-[.sup.18F]fluoroethoxy]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-{5-[2-[.sup.18F]fluoroethoxy]pyridin-3-yl}propanoic acid, tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(5-{4-[2-[.sup.18F]fluoroethoxy]phenyl}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, (3S)-3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]-carbonyl}amino)-3-(5-{4-[2-[.sup.18F]fluoroethoxy]phenyl}pyridin-3-yl)propanoic acid, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{4-[2-[.sup.18F]fluoroethoxy]phenyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-(3-{(3R)-3-[(1-{5-[3-cyano-4-[.sup.18F]fluorophenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(3-cyano-4-[.sup.18F]fluorophenyl)pyridin-3-yl]propanoic acid, tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-cyano-3-[.sup.18F]fluorophenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate, 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-cyano-3-[.sup.18F]fluorophenyl]pyridin-3-yl}propanoic acid, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-[.sup.18F]fluoroethoxy)phenyl]ethynyl}pyridine-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-[.sup.18F]fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[4-(2-[.sup.18F]fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-[.sup.18F]fluoroethoxy)phenyl]ethyl }pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, tert-butyl 4-{3-[(3R)-3-({1-[3-(2-{2-[2-[.sup.18F]fluoroethoxy]ethoxy}ethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate, and 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-{2-[2-[.sup.18F]fluoroethoxy]ethoxy}ethoxy)phenyl]propanoic acid.

14. Compounds of the formula II of claim 9, wherein: R.sup.9 is hydrogen or (C.sub.1-C.sub.4) alkyl; and R.sup.10 is (C.sub.1-C.sub.4) alkyl.

15. Compounds of the formula II of claim 9, wherein: R.sup.9 is hydrogen, methyl, ethyl or tert-butyl; and R.sup.10 is methyl, ethyl or tert-butyl.

Description

DESCRIPTION OF THE FIGURES

(1) FIG. 1: Affinity assay: In the first step human GPIIb/IIIa purified from human platelets was immobilized on a 96-well solid plate. After 48 hours the plates were washed and the unspecific binding sites were blocked with Roti®-Block. 2. In the next step, the plates were simultaneously incubated with a tritium labeled known GPIIb/IIIa binder (.sup.3H) mixed with increasing concentrations of the novel small molecule compounds (inhibitor, .sup.19F). The higher the affinity of the inhibitor, the lower the bound fraction of the tritiated known GPIIb/IIIa binder (.sup.3H) was. The fraction of tritiated compound (.sup.3H), which is not displaced by inhibitor, was measured in a microplate scintillation counter.

(2) FIG. 2: The diagram shows the blood-to-clot ratio versus IC50 values of the investigated compounds. Each point is marked with the accompanying example number. The blood-to-clot ratios decrease with increasing affinity.

(3) FIG. 3: Biodistribution of the compound described in example 41 in mice. The compound was rapidly eliminated from the blood and was quickly excreted over the kidney and liver. There was almost no background in the whole rest of the body after 15 minutes p. i.

(4) FIG. 4: Blood kinetics of the compound described in example 40 in cynomolgus monkey.

(5) PET-imaging was performed continuously from shortly before up to 60 minutes post injection. Venous blood samples were taken at 3, 10, 30 and 60 minutes p.i. and were measured in a gamma-counter (Automatic Gamma Counter Wizard.sup.2 3, Perkin Elmer) and expressed as cpm/mg blood. Additionally, the blood-concentration of the compound was measured from the PET-Image over the whole imaging period and expressed as % ID/g. As already shown in mice, the compound was rapidly eliminated from the blood.

(6) FIG. 5: PET-Imaging of an arterial thrombus in a cynomolgus monkey: The Figure shows an arterial thrombus (arrow 2) which had developed on the surface of a roughened polyethylene catheter tube (PE50). The thrombus is already visible inside the descending Aorta nearby the heart (arrow 1) within the first 15 minutes (left image). There is no signal loss up to 60 minutes (right image). The compound is quickly eliminated from the blood and there is no background in adjacent tissue and organs after 15 minutes (right image).

(7) FIG. 6: PET-Imaging of an arterial thrombus in a cynomolgus monkey: The Figure shows two arterial thrombi (arrow 2) which had developed on the surface of a polyethylene catheter tube (PE50) which was roughened at two parts with a gap in between. There is no signal visible between the thrombi proving that the compound solely binds to thrombus and not to the polymeric tube alone. The thrombus is already visible inside the descending Aorta nearby the heart (arrow 1) within the first 15 minutes (left image). There is no signal loss up to 60 minutes (right image). The compound is quickly eliminated from the blood and there is no background in adjacent tissue or organs after 15 minutes (right image).

(8) FIG. 7: Arterial thrombi removed from monkey 2: The image shows the polyethylene catheter tube (PE50, outer diameter: 1 mm) which was roughened at two parts (⅓) with a gap (2) in between. The thrombus had only developed on the rough parts of the tube-surface and was extremely thin (approximately 1/10th mm [arrow 1] or even less [arrow 3]). This shows that even tiniest thrombi can be detected anywhere in the body.

(9) FIG. 8: PET-Imaging of arterial and venous thrombi in a cynomolgus monkey with the reduced tracer-dosage of 15 MBq per animal: The Figure shows several arterial (arrow 3) and venous (arrow 4) thrombi which had developed on the surface of polyethylene catheter tubes (PE50) which were roughened at some parts with gaps in between. All thrombi could be seen already in the first 15 minutes. However, the contrast was much better after 15 minutes because of the low background. Apart from the thrombogenic catheters another arterial thrombus showed up in the image, which was found in the right carotid artery later on and had most probably developed as a result of vessel damage while the preparation. The heart (left image, arrow 1) is only visible within the first 15 minutes, while the liver (right image, arrow 5) can still be seen up to 60 minutes.

EXPERIMENTAL PART

(10) Abbreviations

(11) TABLE-US-00004 ACN acetonitrile Boc tert-butoxycarbonyl br broad signal (in NMR data) CAN ceric ammonium nitrate CI chemical ionisation d doublet DAD diode array detector dd doublet of doublet ddd doublet of doublet of doublet dt doublet of triplet DMF N,N-dimethylformamide DMSO dimethylsulfoxide EI electron ionisation ELSD evaporative light scattering detector ESI electrospray ionisation EtOAc ethyl acetate EtOH ethanol Fmoc fluorenylmethyloxycarbonyl Fu Fraction unbound Hal halogenide HATU N-[(dimethylamino)(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yloxy)- methylidene]-N-methylmethanaminium hexafluorophosphate HPLC high performance liquid chromatography HT High throughput GBq Giga Bequerel K.sub.2.2.2 4, 7, 13, 16, 21, 24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane K.sub.2CO.sub.3 potassium carbonate MBq Mega Bequerel LCMS Liquid chromatography-mass spectroscopy MWCO Molecular weight cut off MeCN acetonitrile MeOH methanol MS mass spectrometry MTB methyl tert-butyl ether m multiplet mc centred multiplet NH.sub.4Cl ammonium chloride NMR nuclear magnetic resonance spectroscopy: chemical shifts (δ) are given in ppm. q quadruplett (quartet) PMB para-methoxybenzyl Rt Retention time RT room temperature s singlet t triplet TBAF tetrabutylammonium fluoride TEE Transesophageal Echocardiography THF tetrahydrofuran THP tetrahydropyran TIA transient ischemic attack UPLC ultra performance liquid chromatography

(12) Examples were analyzed and characterized by the following analytical methods to determine characteristic retention time and mass spectrum:

(13) TABLE-US-00005 System: Waters Acquity UPLC-MS: Binary Solvent Manager, Sample Manager/Organizer, Column Manager, PDA, ELSD, SQD 3001 Column: Acquity UPLC BEH C18 1.7 50 × 2.1 mm Solvent: A1 = H2O + 0.1% HCOOH A2 = H2O + 0.2% NH3 B1 = Acetonitrile Gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B Flow: 0.8 mL/min Temperature: 60° C. Injection: 2.0 μl Detection: DAD scan range 210-400 nm −> Peak table ELSD Method: MS ESI+, ESI− Switch −> diverse scan ranges possible

(14) Method 1: UPLC (ACN-HCOOH)

(15) Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50×2.1 mm; eluent A: water+0.1% formic acid, eluent B: acetonitril; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min; temperature: 60° C.; injection: 2 μl; DAD scan: 210-400 nm; ELSD

(16) Method 2: UPLC (ACN-NH3)

(17) Instrument: Waters Acquity UPLC-MS SQD 3001; column: Acquity UPLC BEH C18 1.7 50×2.1 mm; eluent A: water+0.2% ammonia Eluent B: acetonitrile; gradient: 0-1.6 min 1-99% B, 1.6-2.0 min 99% B; flow 0.8 ml/min; temperature: 60° C.; injection: 2 μl; DAD scan: 210-400 nm; ELSD

EXAMPLES

Example 1

(3S)-3-[3-(2-Fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(18) ##STR00203##

Example 1a

Methyl 3-[(tert-butoxycarbonyl)amino]-3-(3-hydroxyphenyl)propanoate

(19) ##STR00204##

(20) Methyl 3-amino-3-(3-hydroxyphenyl)propanoate (2.78 g, 14.2 mmol) in THF (70 mL) and triethylamine (3 mL, 21.3 mmol) were added to a solution of di tert.-butyldicarbonate (4.66 g, 21.3 mmol) in THF (70 mL) and the mixture was stirred for 72 hours. Saturated ammonium chloride solution was added and the mixture extracted with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate and concentrated in vacuum. The residue was purified by chromatography on silica gel (ethyl acetate in hexane 0 to 30%) to yield 3.24 g methyl 3-[(tert-butoxycarbonyl)amino]-3-(3-hydroxyphenyl)propanoate.

(21) .sup.1H-NMR (400 MHz, DMSO.sub.d6): δ=1.35 (s, 9 H), 2.56-2.75 (m, 2 H), 3.55 (s, 3 H), 4.81 (m, 1 H), 6.60 (ddd, 1 H), 6.69 (m, 2 H), 7.08 (dd, 1 H), 7.42 (d, 1 H), 9.37 (s, 1 H) ppm.

Example 1b

Methyl 3-[(tert-butoxycarbonyl)amino]-3-[3-(2-fluoroethoxy)phenyl)propanoate

(22) ##STR00205##

(23) To methyl 3-[(tert-butoxycarbonyl)amino]-3-(3-hydroxyphenyl)propanoate (4.46 g, 20 mmol) in THF was added cesium carbonate (9.84 g, 30 mmol) and 1-fluoro-2-iodoethane (5 g, 30 mmol) and the mixture was stirred for 9 hours. After filtration the filtrate was concentrated in vacuum to yield 5.0 g of methyl 3-[(tert-butoxycarbonyl)amino]-3-[3-(2-fluoroethoxy)phenyl)propanoate.

(24) .sup.1H-NMR (400 MHz, CDCl.sub.3): δ=1.43 (br. s, 9 H), 2.83 (m, 2 H), 3.63 (s, 3 H), 4.23 (ddd, 2 H), 4.76 (ddd, 2 H), 5.08 (br., 1 H), 5.48 (br., 1H), 6.82 (dd, 1 H), 6.88 (s, 1 H), 6.91 (d, 1 H), 7.26 (t, 1 H) ppm.

Example 1c

Methyl 3-amino-3-[3-(2-fluoroethoxy)phenyl]propanoate

(25) ##STR00206##

(26) To methyl 3-[(tert-butoxycarbonyl)amino]-3-[3-(2-fluoroethoxy)phenyl)propanoate (5.0 g, 20 mmol) in dichloromethane was added trifluoro acetic acid (5.64 mL, 73 mmol). After stirring for 24 hours at room temperature additional trifluoro acetic acid (1.13 mL) was added and stirring was continued for 20 hours. The mixture was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (methanol in dichloromethane 0% to 40%)) to yield 4.9 g methyl 3-amino-3-[3-(2-fluoroethoxy)phenyl]propanoate.

(27) .sup.1H-NMR (300 MHz, DMSO.sub.d6): δ=2.86-3.12 (m, 2 H), 4.13-4.24 (m, 1 H), 4.24-4.34 (m, 1 H), 4.52-4.75 (m, 2 H), 4.75-4.95 (m, 1 H), 7.00 (dd, 1 H), 7.06 (d, 1 H), 7.12 (d, 1 H), 7.28-7.42 (m, 1 H), 8.44 (br. s., 2H) ppm.

Example 1d

Tert-butyl 4-{3-[(3R)-3-({(1-[3-(2-fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(28) ##STR00207##

(29) (3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidine-3-carboxylic acid (105 mg, 286 μmol, Bioorg. Med. Chem. 13 (2005) 4343-4352, Compound 10) were suspended in 2 ml N,N-dimethylformamide and cooled to 0° C. HATU (117 mg, 308 μmol), a solution of methyl 3-amino-3-[3-(2-fluoroethoxy)phenyl]propanoate (53 mg, 220 μmol) in 3.4 ml N,N-dimethylformamide and N-ethyl-diisopropylamine (0.11 ml, 660 μmol) were added. The mixture was stirred at 0° C. for 5 minutes and at room temperature for 24 hours. Water was added and the mixture extracted with dichloromethane, washed with saturated sodium chloride solution and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on an amino phase column (Separtis® Flash-NH2, ethyl acetate in dichloromethane 0% to 100%) to yield 88 mg of tert-butyl 4-{3-[(3R)-3-({(1-[3-(2-fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(30) UPLC (ACN-HCOOH): Rt.=1.22/1.23 min

(31) MS (ES.sup.+): m/e=592.44 (M+H.sup.+)

Example 1e

3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-fluoroethoxy)phenyl]propanoic acid

(32) ##STR00208##

(33) Tert-butyl 4-{3-[(3R)-3-({(1-[3-(2-fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (67 mg, 102 μmol) was dissolved in methanol (12.4 mL) and barium hydroxide octahydrate (2.2 g, 7.1 mmol) was added. The mixture was stirred at room temperature for one hour and then diluted with brine and diethyl ether. The mixture was acidified with 1 M hydrochloric acid and phases were separated. Concentration of the organic phase gave 70 mg 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-fluoroethoxy)phenyl]propanoic acid

(34) UPLC (ACN-HCOOH): Rt.=1.12/1.14 min

(35) MS (ES.sup.+): m/e=578.3 (M+H.sup.+)

(36) .sup.1H-NMR (500 MHz, DMSO.sub.d6, at 80° C.): δ=0.82-1.05 (m, 2 H), 1.05-1.51 (m, 6 H), 1.40(s, 9 H), 1.56-1.70 (m, 4 H), 2.29-2.41 (m, 3 H), 2.58-2.80 (m, 5 H), 3.20 (br., 3H), 3.91 (d, 2 H), 4.25 (ddd, 2 H), 4.73 (ddd, 2 H), 5.19 (m, 1 H), 6.85 (m, 1 H), 6.94 (m, 2 H), 7.23 (td, 1 H), 8.15 (d, 1 H) ppm.

Example 1f

(3S)-3-[3-(2-Fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(37) To 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[3-(2-fluoroethoxy)phenyl]propanoic acid (65 mg, 90 μmol) in dioxane was added a 4 M solution of hydrochloric acid in dioxane (0.23 ml, 900 μmol) and stirred for 3 hours at room temperature. The solution was concentrated under reduced pressure and the residue was purified by preparative HPLC to yield 8.7 mg of (3S)-3-[5-(2-fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(38) TABLE-US-00006 Column: C18 YMC-ODS AQ 10 μm 170 × 25 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.25 min 10% B, 0.25-10 min 10-50% B Flow: 60 mL/min Temperature: RT Detection: 261 nm Rt.: 4.84-5.73 min

(39) UPLC (ACN-HCOOH): Rt.=0.76 min

(40) MS (ES.sup.+): m/e=478.29 (M+H.sup.+)

(41) .sup.1H-NMR (500 MHz, DMSO.sub.d6, 80° C.): δ=1.20-1.70 (m, 8 H), 1.80 (m, 2 H), 2.17 (br. 1H), 2.25-2.50 (m, 4 H), 2.60-2.71 (m, 3 H), 3.05-3.25 (m, 3 H), 3.72 (br., 3 H), 4.23 (ddd, 2 H), 4.73 (ddd, 2 H), 5.10 (m, 1 H), 6.80 (m, 1 H), 6.91 (m, 2 H), 7.21 (t, 1 H), 8.28 (br., 1 H) ppm.

Example 2

(3S)-3-[4-(2-Fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(42) ##STR00209##

Example 2a

3-Amino-3-(4-hydroxyphenyl)propionic acid methyl ester

(43) ##STR00210##

(44) 5.298 g (29.24 mmol) commercial 3-amino-3-(4-hydroxyphenyl)propionic acid were suspended in 136 ml methanol, the mixture cooled to 0° C. and 3.20 ml (43.86 mmol) thionyl chloride were slowly added. The mixture was stirred at room temperature for 20 hours and concentrated. The residue was treated with saturated sodium hydrogen carbonate solution and extracted with dichloromethane and dichloromethane/2-propanol 8:2. The organic part was concentrated to give 5.09 g (80%) 3-amino-3-(4-hydroxyphenyl)propionic acid methyl ester.

(45) UPLC (ACN-HCOOH): Rt.=0.45 min

(46) MS (ES.sup.+): m/e=179.07 (M+H.sup.+—NH.sub.3)

(47) MS (ES.sup.−): m/e=240.30 (M+HCOO.sup.−)

Example 2b

Tert-butyl 4-[3-((3R)-3-{[1-(4-hydroxyphenyl)-3-methoxy-3-oxopropyl]Carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate

(48) ##STR00211##

(49) 490.75 mg (1.33 mmol) (3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidine-3-carboxylic acid (Bioorg. Med. Chem. 13 (2005) 4343-4352, Compound 10) were suspended in 8 ml N,N-dimethylformamide and cooled to 0° C. 0.545 g (1.43 mmol) HATU, a solution of 200.0 mg (1.0 mmol) 3-amino-3-(4-hydroxy-phenyl)-propionic acid methyl ester in 12 ml N,N-dimethylformamide and 0.53 ml (3.07 mmol) N-ethyl-diisopropylamine were added. The mixture was stirred at 0° C. for 5 minutes and at room temperature for 24 hours. 20 ml water were added and the mixture extracted with dichloromethane, washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuum. Chromatography over 28 g basic silica gel (dichloromethane/ethanol 100/0-95/5-90/10-80/20) gave 465 mg (83%) tert-butyl 4-[3-((3R)-3-{[1-(4-hydroxyphenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate.

(50) UPLC (ACN-HCOOH): Rt.=1.11 min

(51) MS (ES.sup.+): m/e=546.31 (M+H.sup.+)

(52) MS (ES.sup.−): m/e=590.23 (M+HCOO.sup.−)

Example 2c

Tert-butyl 4-{3-[(3R)-3-({1-[4-(2-fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(53) ##STR00212##

(54) 150 mg (0.28 mmol) 4-(3-{(R)-3-[1-(4-hydroxy-phenyl)-2-methoxycarbonyl-ethylcarbamoyl]-piperidin-1-yl}-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester were dissolved in 3 ml tetrahydrofurane. 179 mg (0.55 mmol) cesium carbonate and 91 mg (0.52 mmol) 1-iodo-2-fluoroethane were added. The mixture was stirred at room temperature for 60 hours and filtrated. The filtrate was concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 90 mg (50%) tert-butyl 4-{3-[(3R)-3-({1-[4-(2-fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate and 40 mg starting material.

(55) UPLC (ACN-HCOOH): Rt.=1.24-1.25 min

(56) MS (ES.sup.+): m/e=592.31 (M+H.sup.+)

(57) MS (ES.sup.−): m/e=590.29 (M−H), 636.26 (M+HCOO.sup.−)

Example 2d

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[4-(2-fluoroethoxy)phenyl]propanoic acid

(58) ##STR00213##

(59) 96 mg (0.16 mmol) tert-butyl 4-{3-[(3R)-3-({1-[4-(2-fluoroethoxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 20 ml methanol. 512 mg (1.62 mmol) barium hydroxide octahydrate were added. The mixture was stirred at room temperature for 70 hours and then diluted with 20 ml water. The mixture was acidified with 1 N hydrochloric acid to pH 4 and extracted with 2×40 ml dichloromethane. Concentration of the organic phase gave 93 mg (99%) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[4-(2-fluoroethoxy)phenyl]propanoic acid.

(60) UPLC (ACN-HCOOH): Rt.=1.14-1.16 min

(61) MS (ES.sup.+): m/e=578.30 (M+H.sup.+)

(62) MS (ES.sup.−): m/e=576.30 (M−H), 622.16 (M+HCOO.sup.−)

Example 2e

(3S)-3-[4-(2-Fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(63) ##STR00214##

(64) 93 mg (0.16 mmol) 3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[4-(2-fluoroethoxy)phenyl]propanoic acid ester were dissolved in 3.3 ml dioxane. 0.4 ml (1.6 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 48 hours and then concentrated to give 131 mg which were purified by HPLC:

(65) TABLE-US-00007 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.2% NH3 B = Methanol Gradient: 0-1 min 10% B, 1-8 min 10-70% B Flow: 50 mL/min Temperature: RT Solution: 131 mg/2 mL DMSO/MeOH 1:1 Injection: 2 × 1 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount −11 5.0-5.4  >99% 19 mg −12 5.7-6.0 90.2% 16 mg The fractions were concentrated, mixed with tert.-butanol and lyophilized.

(66) Fraction 12 contained the desired isomer.

(67) UPLC (ACN-HCOOH): Rt.=0.65 min

(68) MS (ES.sup.+): m/e=478.37 (M+H.sup.+)

(69) MS (ES.sup.−): m/e=476.43 (M−H)

Example 3

(3S)-3-[5-(2-Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]-piperidin-3-yl}carbonyl)amino]propanoic acid

(70) ##STR00215##

Example 3a

Tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(71) ##STR00216##

(72) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-hydroxypyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 25e, 800 mg, 1.36 mmol) was dissolved in N,N-dimethylformamide (52 mL). Cesium carbonate (1.1 g, 3.4 mmol) and 2-fluoroethyltosylate (445 mg, 2.04 mmol) were added. The mixture was stirred at room temperature for 3.5 hours, additional cesium carbonate (70 mg, 0.21 mmol) and 2-fluoroethyltosylate (28 mg, 0.13 mmol) were added and stirring was continued for 2.5 hours at room temperature and 17 hours at 5° C. The mixture was quenched by addition of saturated aqueous ammonium chloride solution and extracted with diethyl ether and ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20 to 100% followed by dioxane in ethyl acetate 0 to 50%) to yield 670 mg of tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat.

(73) UPLC (ACN-HCOOH): Rt.=1.24 min

(74) MS (ES.sup.+): m/e=633.5 (M+H.sup.+)

Example 3b

(3S)-3-[5-(2-Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]-piperidin-3-yl}carbonyl)amino]propanoic acid

(75) Tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-fluoroethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat (660 mg, 1.06 mmol) in formic acid (12 mL) was heated for 30 minutes to 60° C. and 10 minutes to 100° C. The solution was concentrated under reduced pressure and the residue was purified by preparative HPLC to yield 311 mg of (3S)-3-[5-(2-fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(76) TABLE-US-00008 Column: C18 YMC-ODS AQ 10 μm 200 × 51 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-1 min 1% B, 1-10 min 1-25% B, Flow: 240 mL/min Temperature: RT Detection: 277 nm Rt.: 5.21-7.05 min

(77) UPLC (ACN-HCOOH): Rt.=0.50 min

(78) MS (ES.sup.+): m/e=479.4 (M+H.sup.+)

(79) .sup.1H-NMR (400 MHz, DMSO.sub.d6): δ=1.13-1.29 (m, 2 H), 1.35-1.77 (m, 7 H), 1.88 (d, 1 H), 2.00 (m, 1 H), 2.21-2.43 (m, 4 H), 2.50-2.78 (m, 3 H), 2.96-3.11 (m, 1 H), 3.15 (d, 1 H), 3.28 (d, 1 H), 3.64 (br., 4 H), 4.30 (ddd, 2 H), 4.75 (ddd, 2 H), 5.09 (m, 1 H), 7.27 (s, 1 H), 8.10 (s, 1 H), 8.16 (s, 1 H), 8.53 (d, 1 H) ppm.

Example 4

(3S)-3-(3-{2-[2-(2-Fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(80) ##STR00217##

Example 4a

Tert-butyl {[3-(benzyloxy)phenyl](phenylsulfonyl)methyl}carbamate

(81) ##STR00218##

(82) To 3-(benzyloxy)benzaldehyde (5 g, 23.6 mmol) and benzenesulfinic acid sodium salt (3.9 g, 23.6 mmol) in THF (23 mL) was added water (51.5 mL), tert-butyl carbamate (2.76 g, 23.6 mmol) and formic acid (2.66 mL, 70 mmol). The mixture was stirred for 4 day and filtrated. The precipitate was washed with water and triturated in hexane containing 9% dichloromethane. After filtration the solids were dried in vacuum to yield 7.24 g of tert-butyl {[3-(benzyloxy)phenyl](phenylsulfonyl)methyl}carbamate.

(83) .sup.1H-NMR (400 MHz, CDCl.sub.3): δ=1.27 (s, 9 H), 5.07 (s, 2 H), 5.73 (d, 1 H), 5.90 (d, 1 H), 6.94-7.14 (m, 3 H), 7.30-7.49 (m, 6 H), 7.55 (t, 2 H), 7.65 (t, 1 H), 7.92 (d, 2 H) ppm.

Example 4b

Tert-butyl methyl 2-{(S)-[3-(benzyloxy)phenyl][(tert-butoxycarbonyl)amino]methyl}propanedioate

(84) ##STR00219##

(85) Tert-butyl {[3-(benzyloxy)phenyl](phenylsulfonyl)methyl}carbamate (3.0 g, 5.93 mmol) was suspended in a toluene (21.6 mL) water (16 mL) mixture. At 0° C. tert-butyl methyl malonate (1.2 mL, 7.1 mmol), cesium carbonate (1.94 g, 5.9 mmol) and 1-[3,5-bis(trifluoromethyl)phenyl]-3-[(1R,2R)-(−)-2-(dimethylamino)cyclohexyl]thiourea (246 mg, 0.59 mmol) was added and the mixture was stirred for 72 hours at 0° C. After storage at −20° C. for 72 hours the mixture was diluted with water and ethyl acetate, after filtration the phases were separated and the aqueous phase extracted with ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (ethyl acetate in hexane 0 to 35%) to yield 2.17 g of enantiomerically enriched tert-butyl methyl 2-{(S)-[3-(benzyloxy)phenyl][(tert-butoxycarbonyl)amino]methyl}propanedioate.

(86) .sup.1H-NMR (400 MHz, CDCl.sub.3): δ=1.20 (s, 4.5 H), 1.36 (s, 9 H), 1.41 (s, 4.5 H), 3.04 (br., 3 H), 3.47 (s, 1.5 H), 3.66 (s, 1.5 H), 3.88 (m, 1 H), 5.09 (s, 2 H), 5.06-5.11 (m, 1H), 6.85-6.93 (m, 2 H), 7.02 (m, 1 H), 7.21 (m, 1 H), 7.28-7.46 (m, 5 H) ppm.

Example 4c

Tert-butyl methyl 2-[(S)-[3-(benzyloxy)phenyl]({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)methyl]propanedioate

(87) ##STR00220##

(88) To tert-butyl methyl 2-{(S)-[3-(benzyloxy)phenyl][(tert-butoxycarbonyl)amino]methyl}propanedioate (600 mg, 1.24 mmol) was added 0° C. cold formic acid (13.8 mL) and the solution was stored at 5° C. for 20 hours. Ice was added and pH was adjusted to 8 by addition of aqueous sodium hydrogen carbonate solution. The aqueous phase was extracted with ethyl acetate. The combined extracts were washed with aqueous sodium hydrogen carbonate solution and brine and dried over sodium sulfate. Concentration under reduced pressure yields 390 mg of raw tert-butyl methyl 2-{(S)-amino[3-(benzyloxy)phenyl]methyl}propanedioate. (3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidine-3-carboxylic acid (447 mg, 1.21 mmol) were suspended in N,N-dimethylformamide (14 mL) and cooled to 0° C. HATU (646 mg, 1.7 mmol), a solution of the raw tert-butyl methyl 2-{(S)-amino[3-(benzyloxy)phenyl]methyl}propanedioate (780 mg, 1.21 mmol) in N,N-dimethylformamide (14 mL) and N-ethyl-diisopropylamine (350 μL, 3.64 mmol) were added. The mixture was stirred at 0° C. for 2 hours. Ice water and saturated ammonium chloride solution was added, the mixture extracted with ethyl acetate and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on an amino phase column (Separtis® Flash-NH2, ethyl acetate in hexane 0 to 100%) to yield 700 mg of tert-butyl methyl-[(S)-[3-(benzyloxy)phenyl]({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)methyl]propanedioate.

(89) UPLC (ACN-HCOOH): Rt.=1.53 min

(90) MS (ES.sup.+): m/e=736.68 (M+H.sup.+)

(91) MS (ES.sup.−): m/e=780.82 (M+HCOO.sup.−)

Example 4d

Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[3-(benzyloxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(92) ##STR00221##

(93) Tert-butyl methyl 2-[(S)-[3-(benzyloxy)phenyl]({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)methyl]propanedioate (700 mg, 0.95 mmol) was solved in formic acid (5.4 mL) and stored for 5 days at room temperature. The mixture was concentrated under reduced pressure to yield 640 g of raw (3S)-3-[3-(benzyloxy)phenyl]-2-(methoxycarbonyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid. The methyl ester in THF (65 mL) and triethylamine (2.5 mL, 18 mmol) was heated to 60° C. for 4 hours. After concentration under reduced pressure the residue was purified by preparative HPLC to yield 147 mg of methyl (3S)-3-[3-(benzyloxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoate.

(94) TABLE-US-00009 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 1% B, 0.5-10 min 1-60% B, Flow: 65 mL/min Temperature: RT Detection: 277 nm Rt.: 7.09-7.40 min

(95) To the free piperidine in dichloromethane (1.5 mL) and triethylamine (0.11 mL) was added di-tert-butyl dicarbonate (90 μL, 0.38 mmol) and the mixture was stirred for 2 hours to yield 159 mg of tert-butyl 4-{3-[(3R)-3-({(1S)-1-[3-(benzyloxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate after concentration in vacuum.

(96) UPLC (ACN-HCOOH): Rt.=1.41 min

(97) MS (ES.sup.+): m/e=636.59 (M+H.sup.+)

(98) MS (ES.sup.−): m/e=680.44 (M+HCOO.sup.−)

Example 4e

Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[3-hydroxyphenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(99) ##STR00222##

(100) Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[3-(benzyloxy)phenyl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (650 mg, 1.02 mmol) was dissolved in ethyl acetate (45 mL) and methanol (7.4 mL) and palladium on charcoal (65 mg, 10%) was added. The mixture was shaken under a hydrogen atmosphere for 16 hours filtrated through celite which were washed with methanol. The filtrate was concentrated and purified by chromatography on silica gel (methanol in ethyl acetate 0% to 25%) to yield 422 mg of tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(3-hydroxyphenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(101) .sup.1H-NMR (400 MHz, DMSO.sub.d6, at 80° C.): δ=1.01 (m, 2 H), 1.26-1.53 (m, 4 H), 1.41 (s, 9 H), 1.65 (m, 4 H), 1.83 (m, 1 H), 2.23-2.38 (m, 3 H), 2.65-2.76 (m, 5 H), 3.57 (s, 3 H), 3.92 (m, 3 H), 5.19 (q, 1 H), 6.64 (d, 1 H), 6.72 (m, 2 H), 7.09 (t, 1 H), 8.05 (d, 1 H), 9.04 (br., 1 H) ppm

(102) UPLC (ACN-HCOOH): Rt.=1.14 min

(103) MS (ES.sup.+): m/e=546.53 (M+H.sup.+)

(104) MS (ES.sup.−): m/e=590.43 (M+HCOO.sup.−)

Example 4f

Tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(3-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}phenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(105) ##STR00223##

(106) To tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(3-hydroxyphenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (26 mg, 50 μmol) in DMF (6.6 mL) was added cesium carbonate (38.8 mg, 120 μmol) and 2-[2-(2-fluoroethoxy)ethoxy]ethyl 4-methylbenzenesulfonate (22 mg, 70 μmol) while stirring at room temperature. After 5 hours toluene was added and the mixture was concentrated in vacuum. The DMF free residue was purified by preparative thin layer chromatography on silica gel (dichloromethane in ethyl acetate 30%) to yield 21 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(3-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}phenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(107) .sup.1H-NMR (400 MHz, DMSO.sub.d6, at 80° C.): δ=1.02 (m, 2 H), 1.25-1.51 (m, 5 H), 1.41 (s, 9 H), 1.55-1.70 (m, 4 H), 1.82 (m, 1 H), 2.26-2.38 (m, 3 H), 2.73-2.81 (m, 4 H), 3.40 (m, 1 H), 3.56-3.65 (m, 5 H), 3.58 (s, 3 H), 3.69-3.74 (m, 1 H), 3.74-3.81 (m, 2 H), 3.91 (br., 2 H), 4.06-4.14 (m, 2 H) 4.50 (ddd, 2 H), 5.21 (q, 1 H), 6.82 (dd, 1 H), 6.85-6.96 (m, 2 H), 7.21 (t, 1 H), 8.08 (d, 1 H) ppm.

(108) UPLC (ACN-HCOOH): Rt.=1.26 min

(109) MS (ES.sup.+): m/e=680.54 (M+H.sup.+)

(110) MS (ES.sup.−): m/e=724.50 (M+HCOO.sup.−)

Example 4 g

(3S)-3-(3-{2-[2-(2-Fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(111) Tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(3-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}phenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (20.3 mg, 27 μmol) was solved in tert.-butanol (0.77 mL) and methanol (0.76 mL) and barium hydroxide octahydrate (42 mg, 0.13 mmol) was added. After stirring for 60 minutes room temperature the solvent was distilled off at 0° C. by high vacuum. The residue was solved in water (1 mL) and acidified by formic acid (2 mL). After 18 hours at 5° C. additional formic acid (2 mL) was added. After 3 hours at room temperature the solvent was distilled off at 0° C. by high vacuum and the residue was purified by preparative HPLC to yield 8.4 mg of (3S)-3-(3-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(112) TABLE-US-00010 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 15% B, 0.5-10 min 15-70% B, Flow: 65 mL/min Temperature: RT Detection: 285 nm Rt.: 3.48-4.19 min

(113) UPLC (ACN-HCOOH): Rt.=0.69 min

(114) MS (ES.sup.+): m/e=566.41 (M+H.sup.+)

(115) MS (ES.sup.−): m/e=564.37 (M−H)

Example 5

(3S)-3-(5-{2-[2-(2-Fluoroethoxy)ethoxy]ethoxy}pyridine-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(116) ##STR00224##

Example 5a

Tert-butyl {[5-(benzyloxy)pyridin-3-yl](phenylsulfonyl)methyl}carbamate

(117) ##STR00225##

(118) To 5-(Benzyloxy)pyridine-3-carbaldehyde (3.61 g, 16.9 mmol, Harrowven, D. C. et al Tetrahedron, 2001 57 p. 4447-4454) and benzenesulfinic acid sodium salt (2.7 g, 16.6 mmol) in THF (16.3 mL) was added water (36.3 mL), tert-butyl carbamate (1.94 g, 16.6 mmol) and formic acid (1.9 mL, 49 mmol). The mixture was stirred for 4 day and filtrated. The filtrate was stirred for 2 additional days and filtrated again. The formed precipitates were washed with water and triturated in hexane containing 9% dichloromethane. After filtration the solids were dried in vacuum to yield 3.17 g of tert-butyl {[5-(benzyloxy)pyridin-3-yl](phenylsulfonyl)methyl}carbamate.

(119) .sup.1H-NMR (400 MHz, CDCl.sub.3): δ=1.27 (s, 9 H), 5.13 (s, 2 H), 5.83 (d, 1 H), 5.97 (d, 1 H), 7.32-7.50 (m, 6 H), 7.53-7.63 (m, 2 H), 7.68 (t, 1 H), 7.93 (d, 2 H), 8.27 (s, 1 H), 8.44 (d, 1 H) ppm.

Example 5b

Tert-butyl methyl 2-{(S)-[5-(benzyloxy)pyridin-3-yl][(tert-butoxycarbonyl)amino]methyl}propanedioate

(120) ##STR00226##

(121) Tert-butyl {[5-(benzyloxy)pyridin-3-yl](phenylsulfonyl)methyl}carbamate (2.2 g, 4.84 mmol) was suspended in a toluene (16.5 ML) water (13 mL) mixture. At 0° C. tert-butyl methyl malonate (1.0 mL, 5.8 mmol), cesium carbonate (1.58 g, 4.84 mmol) and 1-[3,5-bis(trifluoromethy)phenyl]-3-[(1R,2R)-(−)-2-(dimethylamino)cyclohexyl]thiourea (200 mg, 0.48 mmol) was added and the mixture was stirred for 48 hours at 0° C. After storage at 5° C. for 72 hours the mixture was diluted with water and ethyl acetate, the phases were separated and the aqueous phase extracted with ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated. The residue was purified by chromatography on silica gel (ethyl acetate in hexane 0% to 60%) to yield 1.54 g of enantiomerically enriched tert-butyl methyl 2-{(S)-[5-(benzyloxy)pyridin-3-yl][(tert-butoxycarbonyl)amino]methyl}propanedioate.

(122) .sup.1H-NMR (300 MHz, CDCl.sub.3): δ=1.36 (s, 4.5 H), 1.43 (s, 9 H), 1.48 (s, 4.5 H), 3.65 (s, 1.5 H), 3.76-3.87 (m, 1H), 3.77 (s, 1.5 H), 5.10 (s, 2 H), 5.48 (br., 1 H), 6.27 (br., 1 H), 7.26 (s, 1 H), 7.35-7.44 (m, 5 H), 8.21 (d, 1 H), 8.28 (s, 1 H) ppm.

Example 5c

Tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(123) ##STR00227##

(124) To (3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidine-3-carboxylic acid (1.91 g, 5.18 mmol) in 1,2-dimethoxyethane (13.5 mL) was added N-hydroxysuccinimide (0.60 g, 5.18 mmol) and 1,3-dicyclohexyl carbodiimide (1.18 g, 5.7 mmol). The solution was stirred for 4 hours at room temperature while a precipitate formed. The mixture was then cooled to 0° C. filtrated and the solid washed with diethyl ether. The filtrate and the diethyl ether wash were combined and concentrated to yield 2.61 g of raw tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(125) UPLC (ACN-HCOOH): Rt.=1.13 min

(126) MS (ES.sup.+): m/e=466.31 (M+H.sup.+)

Example 5d

Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(127) ##STR00228##

(128) To tert-butyl methyl 2-{(S)-[5-(benzyloxy)pyridin-3-yl][(tert-butoxycarbonyl)amino]methyl}propanedioate in dioxane (15 mL) was added a 4 M solution of hydrochloric acid in dioxane (11.2 mL, 45 mmol) and stirred for 20 hours. The mixture was diluted with dioxane and toluene and concentrated under reduced pressure. The dilution and concentration procedure was repeated with toluene and dichloromethane to yield 1.64 g of raw 2-[(S)-amino-(5-benzyloxy)pyridin-3-yl)methyl]malonic acid monomethyl ester. The monomethyl ester was cooled to 0° C. in DMF (18 mL) and a solution of tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (3.0 g, 5.15 mmol) and triethylamine (1.94 mL, 13.9 mmol) in dichloromethane (18 mL). The mixture was stirred at 0° C. for 21 hours and then heated to 60° C. for one hour. After cooling to room temperature saturated aqueous ammonium chloride solution was added. Phases were separated and the aqueous phase was extracted with diethyl ether and ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated in vacuum. The residue was purified by chromatography on silica gel (methanol in ethyl acetate 0% to 15%) to yield 1.4 g of tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(129) UPLC (ACN-HCOOH): Rt.=1.25 min

(130) MS (ES.sup.+): m/e=637.6 (M+H.sup.+)

(131) MS (ES.sup.−): m/e=681.5 (M+HCOO.sup.−)

Example 5e

Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(hydroxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(132) ##STR00229##

(133) Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (650 mg, 1.02 mmol) was dissolved in ethyl acetate (45 mL) and methanol (7.4 mL) and palladium on charcoal (65 mg, 10%) was added. The mixture was shaken under a hydrogen atmosphere for 16 hours filtrated through celite which were washed with methanol. The filtrate was concentrated and purified by chromatography on silica gel (methanol in ethyl acetate 0% to 25%) to yield 422 mg of tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(134) .sup.1H-NMR (400 MHz, DMSO.sub.d6, at 80° C.): δ=1.00 (m, 2 H), 1.26-1.55 (m, 4 H), 1.40 (s, 9 H), 1.65 (m, 4 H), 1.83 (m, 1 H), 2.17-2.40 (m, 3 H), 2.63-2.74 (m, 2 H), 2.75-2.90 (m, 3 H), 3.58 (s, 3 H), 3.90 (m, 3 H), 5.19 (m, 1 H), 7.08 (d, 1 H), 7.94-8.07 (m, 2 H), 8.16 (d, 1 H), 9.57 (br., 1 H) ppm.

(135) UPLC (ACN-HCOOH): Rt.=0.95 min

(136) MS (ES.sup.+): m/e=547.4 (M+H.sup.+)

Example 5f

Tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(137) ##STR00230##

(138) To tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (30 mg, 60 μmol) in DMF (7.6 mL) was added cesium carbonate (44.7 mg, 140 μmol) and 2-[2-(2-fluoroethoxy)ethoxy]ethyl 4-methylbenzenesulfonate (25 mg, 80 μmol) while stirring at room temperature. After 5 hours toluene was added and the mixture was concentrated in vacuum. The DMF free residue was purified by preparative thin layer chromatography on silica gel (ethyl acetate) to yield 16.7 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(139) .sup.1H-NMR (400 MHz, MeOD): δ=1.00-1.19 (m, 2 H), 1.40-1.60 (m, 5 H), 1.45 (s, 9 H), 1.73 (m, 4 H), 1.94 (m, 1 H), 2.27-2.54 (m, 3 H), 2.73 (br., 2 H), 2.91 (m, 3 H), 3.66 (s, 3 H), 3.64-3.72 (m, 7 H), 3.87 (m, 2 H), 4.06 (br., 3 H), 4.23 (m, 2 H), 4.50 (ddd, 2 H), 5.36 (t, 1 H), 7.41 (dd, 1 H), 8.17 (d, 1 H), 8.13 (d, 1 H) ppm.

(140) UPLC (ACN-HCOOH): Rt.=1.10 min

(141) MS (ES.sup.+): m/e=681.3 (M+H.sup.+)

(142) MS (ES.sup.−): m/e=725.5 (M+HCOO.sup.−)

Example 5 g

(3S)-3-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(143) Tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (16.5 mg, 22 μmol) as solved in tert.-butanol (0.62 mL) and methanol (0.6 mL) and barium hydroxide octahydrate (34 mg, 315 μmol) was added. After stirring for 45 minutes room temperature the solvent was distilled off at 0° C. by high vacuum. The residue was solved in water (0.3 mL) and acidified by formic acid (0.9 mL). After 18 hours at 5° C. the solvent was distilled off at 0° C. by high vacuum and the residue was purified by preparative HPLC to yield 1.6 mg of (3R)-3-(5-{2-[2-(2-fluoroethoxy)ethoxy]ethoxy}pyridin-3-yl)-3-[({(3S)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(144) TABLE-US-00011 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 5% B, 0.5-6 min 5-40% B, Flow: 150 mL/min Temperature: RT Detection: 285 nm Rt: 2.36-2.45 min

(145) UPLC (ACN-HCOOH): Rt.=0.55 min

(146) MS (ES.sup.+): m/e=567.4 (M+H.sup.+)

(147) MS (ES.sup.−): m/e=565.4 (M−H),

Example 6

(3S)-3-{5-[3-(2-Fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(148) ##STR00231##

Example 6a

Tert-butyl 4-{3-[(3R)-3-({1-[5-(3-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(149) ##STR00232##

(150) To 400.0 mg (0.66 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 16 ml toluene were added 15.17 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 108.6 mg (0.79 mmol) (3-hydroxyphenyl)boronic acid in 4.0 ml ethanol and 118.3 mg (2.04 mmol) potassium fluoride in 4.0 ml water. The mixture was stirred at 100° C. for 26 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 236 mg (58%) tert-butyl 4-{3-[(3R)-3-({1-[5-(3-hydroxyphenyl)pyridin-3-yl]-3-m ethoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(151) UPLC (ACN-HCOOH): Rt=1.10 min

(152) MS (ES.sup.+): m/e=624.70 (M+H.sup.+)

(153) MS (ES.sup.−): m/e=621.46 (M−H), 667.57 (M+HCOO.sup.−)

Example 6b

Tert-butyl 4-{3-[(3R)-3-{[1-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(154) ##STR00233##

(155) 128 mg (0.21 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(3-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 2.25 ml tetrahydrofurane. 134 mg (0.41 mmol) cesium carbonate and 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added. The mixture was stirred at room temperature for 70 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 48 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 70 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 24 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane, 2 ml tetrahydrofurane and 134 mg (0.41 mmol) cesium carbonate were added and the mixture stirred at room temperature for 24 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 24 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 24 hours. 68 mg (0.39 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 70 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 100 mg (65%) tert-butyl 4-{3-[(3R)-3-{[1-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(156) UPLC (ACN-HCOOH): Rt.=1.20 min

(157) MS (ES.sup.+): m/e=669.3 (M+H.sup.+)

(158) MS (ES.sup.−): m/e=713.5 (M+HCOO.sup.−)

Example 6c

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid

(159) ##STR00234##

(160) 95 mg (0.14 mmol) Tert-butyl 4-{3-[(3R)-3-{[1-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 17 ml methanol. 448 mg (1.42 mmol) barium hydroxide octahydrate were added. The mixture was stirred at room temperature for 20 hours and then concentrated to give 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[3-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid.

(161) UPLC (ACN-HCOOH): Rt.=1.12 min

(162) MS (ES.sup.+): m/e=655.5 (M+H.sup.+)

(163) MS (ES.sup.−): m/e=653.6 (M−H)

Example 6d

(3S)-3-{5-[3-(2-Fluoroethoxy)phenyl]pyridin-3-yl}-3-{[(3R)-1-(3-piperidin-4-yl-propionyl)piperidine-3-carbonyl]amino}propionic acid

(164) ##STR00235##

(165) The mixture obtained in example 9c containing 93 mg (0.14 mmol) 4-{3-[(R)-3-(2-carboxy-1-{5-[3-(2-fluoro-ethoxy)-phenyl]-pyridin-3-yl}-ethylcarbamoyl)-piperidin-1-yl]-3-oxo-propyl}-piperidine-1-carboxylic acid tert-butyl ester was dissolved in 8.7 ml dioxane. 1.07 ml (4.26 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 20 hours. 0.178 ml (0.71 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 24 hours. 8.0 ml dioxane and 0.178 ml (0.71 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 72 hours and then concentrated. To the residue was added a little amount of water and saturated sodium hydrogen carbonate solution to get a pH=6. The mixture was concentrated and extracted with ethyl acetate/ethanol 9:1 and with dichloromethane/methanol 9:1. The organic solutions were filtered, combined and concentrated to give 55 mg which were purified by HPLC:

(166) TABLE-US-00012 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = Methanol Gradient: 0-1 min 15% B, 1-8 min 15-70% B Flow: 50 mL/min Temperature: RT Solution: 55 mg/2 mL DMSO/MeOH 1:1 Injection: 2 × 1 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount 11 7.2-7.8 78.7% 8 mg 12 7.8-7.2 74.2% 2 mg 13 8.2-9.0 97.3% 9 mg The fractions were concentrated.

(167) Fraction 13 contained the desired isomer.

(168) UPLC (ACN-HCOOH): Rt.=0.95 min

(169) MS (ES.sup.+): m/e=555.12 (M+H.sup.+)

(170) MS (ES.sup.−): m/e=553.17 (M−H)

Example 7

(3S)-3-{5-[4-(2-Fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(171) ##STR00236##

Example 7a

Tert-butyl 4-{3-[(3R)-3-({1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(172) ##STR00237##

(173) To 300.0 mg (0.49 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 12 ml toluene were added 11.4 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 81.5 mg (0.59 mmol) (4-hydroxyphenyl)boronic acid in 3.0 ml ethanol and 88.7 mg (1.53 mmol) potassium fluoride in 3.0 ml water. The mixture was stirred at 100° C. for 4 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 218 mg (71%) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-m ethoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(174) UPLC (ACN-HCOOH): Rt.=1.02 min

(175) MS (ES.sup.+): m/e=624.8 (M+H.sup.+)

(176) MS (ES.sup.−): m/e=621.5 (M−H), 667.6 (M+HCOO.sup.−)

Example 7b

Tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate

(177) ##STR00238##

(178) 120 mg (0.19 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 2.11 ml tetrahydrofurane. 126 mg (0.39 mmol) cesium carbonate and 64 mg (0.37 mmol) 1-iodo-2-fluoroethane were added. The mixture was stirred at room temperature for 70 hours. 64 mg (0.37 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 48 hours. 64 mg (0.37 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 70 hours. 64 mg (0.37 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 24 hours. 64 mg (0.37 mmol) 1-iodo-2-fluoroethane, 2 ml tetrahydrofurane and 126 mg (0.39 mmol) cesium carbonate were added and the mixture stirred at room temperature for 24 hours. 64 mg (0.37 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 24 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 84 mg (62%) tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate.

(179) UPLC (ACN-HCOOH): Rt.=1.16 min

(180) MS (ES.sup.+): m/e=669.3 (M+H.sup.+)

(181) MS (ES.sup.−): m/e=713.5 (M+HCOO.sup.−)

Example 7c

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid

(182) ##STR00239##

(183) 76 mg (0.11 mmol) tert-butyl 4-(3-{(3R)-3-[(1-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate were dissolved in 14 ml methanol. 358.5 mg (1.14 mmol) barium hydroxide octahydrate were added. The mixture was stirred at room temperature for 20 hours and then concentrated to give 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid.

(184) UPLC (ACN-HCOOH): Rt.=1.08 min

(185) MS (ES.sup.+): m/e=655.5 (M+H.sup.+)

(186) MS (ES.sup.−): m/e=653.5 (M−H)

Example 7d

(3S)-3-{5-[4-(2-Fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(187) ##STR00240##

(188) The mixture obtained in example 7c containing 74 mg (0.11 mmol) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[4-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid was dissolved in 6.9 ml dioxane. 0.85 ml (3.39 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 48 hours. 0.141 ml (0.56 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 24 hours and then concentrated. To the residue was added a little amount of water and saturated sodium hydrogen carbonate solution to get a pH=6. The mixture was concentrated and extracted with ethyl acetate/ethanol 9:1. The organic solutions were filtered and concentrated to give 49 mg which were purified by HPLC:

(189) TABLE-US-00013 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = Methanol Gradient: 0-1 min 10% B, 1-8 min 10-50% B Flow: 50 mL/min Temperature: RT Solution: 49 mg/2.1 mL DMSO/MeOH 1:1 Injection: 3 × 0.7 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount 11 5.2-5.8 91.7% 11 mg 12 6.0-6.9 95.5% 12 mg 13 5.8-6.0 56.5% 15 mg 35.4% The fractions were concentrated.

(190) Fraction 12 contained the desired isomer.

(191) UPLC (ACN-HCOOH): Rt. =0.89 min

(192) MS (ES.sup.+): m/e=555.11 (M+H.sup.+)

(193) MS (ES.sup.−): m/e=553.16 (M−H)

Example 8

(3S)-3-{5-[2-(2-Fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(194) ##STR00241##

Example 8a

3-Amino-3-(5-bromopyridin-3-yl)propionic acid

(195) ##STR00242##

(196) 9.50 g (51.07 mmol) 5-bromopyridine-3-carbaldehyde were suspended in 22 ml ethanol. 5.31 g (51.07 mmol) propanedioic acid and 8.27 g (107.25 mmol) ammonium acetate were added. The mixture was refluxed for 4 hours and after cooling to room temperature filtrated. The residue was washed with cold ethanol and dried in vacuum at 45° C. to give 8.69 g (69%) 3-amino-3-(5-bromo-pyridin-3-yl)propionic acid.

(197) .sup.1H-NMR (300 MHz, DMSO-d.sub.6): δ=3.03 (dd, 2H), 4.71 (br., 1H), 8.24 (t, 1H), 8.68 (d, 1H), 8.75 (d, 1H) ppm.

Example 8b

3-Amino-3-(5-bromopyridin-3-yl)propionic acid methyl ester

(198) ##STR00243##

(199) 9.54 g (38.93 mmol) 3-amino-3-(5-bromopyridin-3-yl)propionic acid were suspended in 158 ml methanol and the mixture cooled to 0° C. 4.26 ml (58.39 mmol) thionyl chloride were slowly added. The mixture was stirred at room temperature for 20 hours and concentrated. The residue was treated with saturated sodium hydrogen carbonate solution and extracted with dichloromethane. The organic part was dried with sodium sulfate and concentrated. Chromatography over silica gel (dichloromethane/ethanol 100/0-50/50) gave 5.84 g (52%) 3-amino-3-(5-bromopyridin-3-yl)-propionic acid methyl ester.

(200) UPLC (ACN-NH3): Rt.=0.74 min

(201) MS (ES.sup.+): m/e=261.2 (M+H.sup.+)

(202) .sup.1H-NMR (300 MHz, CDCl.sub.3): δ=2.68 (d, 2H), 3.71 (s, 3H), 4.48 (t, 1H), 7.91-7.95 (m, 1H), 8.53 (d, 1H), 8.59 (d, 1H) ppm.

Example 8c

Tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(203) ##STR00244##

(204) 3.324 g (9.02 mmol) (3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidine-3-carboxylic acid (Bioorg. Med. Chem. 13 (2005) 4343-4352, Compound 10) were suspended in 52 ml N,N-dimethylformamide and cooled to 0° C. 3.694 g (9.71 mmol) HATU, a solution of 1.798 g (6.94 mmol) 3-amino-3-(5-bromo-pyridin-3-yl)-propionic acid methyl ester in 78 ml N,N-dimethylformamide and 3.56 ml (20.82 mmol) N-ethyl-diisopropylamine were added. The mixture was stirred at 0° C. for 5 minutes and at room temperature for 24 hours. 160 ml water were added and the mixture extracted with 280 ml dichloromethane. The organic phase was washed with water, dried over sodium sulfate and concentrated in vacuum. Chromatography over 55 g basic silica gel (dichloromethane/ethanol 100/0-97/3-94/6) gave 4395 mg (104%) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(205) UPLC (ACN-HCOOH): Rt.=1.18 min

(206) MS (ES.sup.+): m/e=511.3 (M+H.sup.+-BOC)

(207) MS (ES.sup.−): m/e=609.5 (M−H)

Example 8d

Tert-butyl 4-{3-[(3R)-3-({1-[5-(2-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(208) ##STR00245##

(209) To 400.0 mg (0.66 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate in 16 ml toluene were added 15.17 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 108.6 mg (0.79 mmol) (2-hydroxyphenyl)boronic acid in 4.0 ml ethanol and 118.3 mg (2.04 mmol) potassium fluoride in 4.0 ml water. The mixture was stirred at 100° C. for 20 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 240 mg (59%) tert-butyl 4-{3-[(3R)-3-({1-[5-(2-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(210) UPLC (ACN-HCOOH): Rt.=1.02 min

(211) MS (ES.sup.+): m/e=624.58 (M+H.sup.+)

(212) MS (ES.sup.−): m/e=621.55 (M−H), 667.57 (M+HCOO.sup.−)

Example 8e

Tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate

(213) ##STR00246##

(214) 124 mg (0.20 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(2-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 2.2 ml tetrahydrofurane. 130 mg (0.40 mmol) cesium carbonate and 66 mg (0.38 mmol) 1-iodo-2-fluoroethane were added. The mixture was stirred at room temperature for 90 hours. 66 mg (0.38 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 20 hours. 66 mg (0.38 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 60 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 80 mg (54%) tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate.

(215) UPLC (ACN-HCOOH): Rt.=1.18 min

(216) MS (ES.sup.+): m/e=669.57 (M+H.sup.+)

(217) MS (ES.sup.−): m/e=667.57 (M−H), 713.62 (M+HCOO.sup.−)

Example 8f

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid

(218) ##STR00247##

(219) 73 mg (0.11 mmol) tert-butyl 4-(3-{(3R)-3-[(1-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}-3-methoxy-3-oxopropyl)carbamoyl]piperidin-1-yl}-3-oxopropyl)piperidine-1-carboxylate were dissolved in 13 ml methanol. 344 mg (1.09 mmol) barium hydroxide octahydrate were added. The mixture was stirred at room temperature for 20 hours and then concentrated to give 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid.

(220) UPLC (ACN-HCOOH): Rt.=1.09 min

(221) MS (ES.sup.+): m/e=655.5 (M+H.sup.+)

(222) MS (ES.sup.−): m/e=653.5 (M−H), 622.16 (M+HCOO.sup.−)

Example 8 g

(3S)-3-{5-[2-(2-Fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(223) ##STR00248##

(224) The mixture obtained in example 8f containing 71 mg (0.11 mmol) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-{5-[2-(2-fluoroethoxy)phenyl]pyridin-3-yl}propanoic acid was dissolved in 6.6 ml dioxane. 0.81 ml (3.25 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 20 hours. 0.136 ml (0.54 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 24 hours. 6.0 ml dioxane and 0.136 ml (0.54 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 24 hours and then concentrated. To the residue was added a little amount of water and saturated sodium hydrogen carbonate solution to get a pH=6. The mixture was concentrated and extracted with ethyl acetate/ethanol 9:1 and with dichloromethane/methanol 9:1. The organic solutions were filtered, combined and concentrated to give 76 mg which were purified by HPLC:

(225) TABLE-US-00014 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = Methanol Gradient: 0-1 min 15% B, 1-8 min 15-60% B Flow: 50 mL/min Temperature: RT Solution: 76 mg/2.1 mL DMSO/MeOH 1:1 Injection: 3 × 0.7 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount 11 6.0-6.6 83.0% 10 mg 12 6.6-7.0 61.5%  4 mg 13 7.0-7.8 98.2% 11 mg The fractions were concentrated.

(226) Fraction 13 contained the desired isomer.

(227) UPLC (ACN-HCOOH): Rt. =0.88 min

(228) MS (ES.sup.+): m/e=555.08 (M+H.sup.+)

(229) MS (ES.sup.−): m/e=553.18 (M−H)

Example 9

(3S)-3-[5-(3-Cyano-4-fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(230) ##STR00249##

Example 9a

Tert-butyl 4-{3-[(3R)-3-({1-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(231) ##STR00250##

(232) To 300.0 mg (0.49 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 12 ml toluene were added 11.4 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 97.4 mg (0.59 mmol) (3-cyano-4-fluoro-phenyl)boronic acid in 3.0 ml ethanol and 88.7 mg (1.53 mmol) potassium fluoride in 3.0 ml water. The mixture was stirred at 100° C. for 3 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 206 mg (58%) tert-butyl 4-{3-[(3R)-3-({1-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(233) UPLC (ACN-HCOOH): Rt.=1.23 min

(234) MS (ES.sup.+): m/e=652.3 (M+H.sup.+)

(235) MS (ES.sup.−): m/e=648.5 (M−H), 694.5 (M+HCOO.sup.−)

Example 9b

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]propanoic acid

(236) ##STR00251##

(237) 100 mg (0.15 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 5 ml tetrahydrofurane and treated with 2.5 ml 0.1N sodium hydroxide solution. The mixture was stirred for 15 minutes and concentrated to give 97 mg (99%).

(238) UPLC (ACN-HCOOH): Rt.=1.13 min

(239) MS (ES.sup.+): m/e=636.5 (M+H.sup.+)

(240) MS (ES.sup.−): m/e=634.5 (M−H)

Example 9c

(3S)-3-[5-(3-Cyano-4-fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(241) ##STR00252##

(242) The mixture obtained in example 9b containing 97 mg (0.15 mmol) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(3-cyano-4-fluorophenyl)pyridin-3-yl]propanoic acid was dissolved in 9.6 ml dioxane. 0.39 ml (1.57 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 20 hours and then concentrated. To the residue was added a little amount of water and saturated sodium hydrogen carbonate solution to get a pH=6. The mixture was concentrated and extracted with dichloromethane/2-propanol 8:2. The organic solutions were filtered and concentrated to give 44 mg which were purified by HPLC:

(243) TABLE-US-00015 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.2% NH3 B = Methanol Gradient: 0-1 min 15% B, 1-12 min 15-55% B Flow: 50 mL/min Temperature: RT Solution: 41 mg/2.2 mL DMF/MeOH 1:1 Injection: 2 × 1.1 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount 11 5.52-5.82 78%   7 mg 12 6.00-6.34 91% 7.5 mg The fractions were concentrated, mixed with tert.-butanol and lyophilized.

(244) Fraction 12 contained the desired isomer.

(245) UPLC (ACN-HCOOH): Rt.=0.95 min

(246) MS (ES.sup.+): m/e=536.11 (M+H.sup.+)

(247) MS (ES.sup.−): m/e=534.11 (M−H)

Example 10

(3S)-3-[5-(4-Cyano-3-fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(248) ##STR00253##

Example 10a

Tert-butyl 4-{3-[(3R)-3-({1-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(249) ##STR00254##

(250) To 300.0 mg (0.49 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 12 ml toluene were added 11.4 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 97.4 mg (0.59 mmol) (4-cyano-3-fluoro-phenyl)boronic acid in 3.0 ml ethanol and 57.2 mg (0.98 mmol) potassium fluoride in 3.0 ml water. The mixture was stirred at 100° C. for 10 hours and at 60° C. for 20 hours, diluted with water and extracted with ethyl acetate and sodium hydrogen carbonate solution. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 157 mg (44%) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(251) UPLC (ACN-HCOOH): Rt.=1.23 min

(252) MS (ES.sup.+): m/e=652.3 (M+H.sup.+)

(253) MS (ES.sup.−): m/e=648.5 (M−H), 694.6 (M+HCOO.sup.−)

Example 10b

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]propanoic acid

(254) ##STR00255##

(255) 220 mg (0.34 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 11 ml tetrahydrofurane and treated with 4.1 ml 0.1N sodium hydroxide solution. The mixture was stirred for 15 minutes and concentrated to give 215 mg (100%).

(256) UPLC (ACN-HCOOH): Rt.=1.14 min

(257) MS (ES.sup.+): m/e=638.2 (M+H.sup.+)

(258) MS (ES.sup.−): m/e=634.5 (M−H)

Example 10c

(3S)-3-[5-(4-Cyano-3-fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(259) ##STR00256##

(260) The mixture obtained in example 10b containing 215 mg (0.34 mmol) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-cyano-3-fluorophenyl)pyridin-3-yl]propanoic acid was dissolved in 20.6 ml dioxane. 0.85 ml (3.4 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 20 hours and then concentrated. To the residue was added a little amount of water and saturated sodium hydrogen carbonate solution to get a pH=6. The mixture was concentrated and extracted with dichloromethane/2-propanol 8:2. The organic solutions were filtered and concentrated to give 205 mg, 203 mg of which were purified by HPLC:

(261) TABLE-US-00016 System: Dionex: Pump P 580, Gilson: Liquid Handler 215, Knauer: UV-Detektor K-2501 Column: Chiralcel OZ-H 5 μm 250 × 30 mm Solvent: Ethanol/Methanol 50:50 Flow: 30 mL/min Temperature: RT Solution: 203 mg/7.6 mL EtOH/MeOH 1:1 Injection: 4 × 1.9 mL Detection: UV 254 nm Fractions: Rt. in min DAD TAC Amount 11 5.4-7.1 >99.9% 60 mg 12 10.4-12.2  98.9% 29 mg The fractions were concentrated and dried in the high vacuum.

(262) Fraction 12 contained the desired isomer.

(263) MS (ES.sup.+): m/e=536.4 (M+H.sup.+)

(264) MS (ES.sup.−): m/e=534.4 (M−H), 680.4 (M+HCOO.sup.−)

Example 11

(3S)-3-[5-(4-Fluoro-3-nitrophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(265) ##STR00257##

Example 11a

Tert-butyl 4-{3-[(3R)-3-({1-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(266) ##STR00258##

(267) To 300.0 mg (0.49 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 12 ml toluene were added 11.4 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 109.2 mg (0.59 mmol) (4-fluoro-3-nitro-phenyl)boronic acid in 3.0 ml ethanol and 88.7 mg (1.53 mmol) potassium fluoride in 3.0 ml water. The mixture was stirred at 100° C. for 9 hours and at 60° C. for 20 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 147 mg (40%) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(268) UPLC (ACN-HCOOH): Rt.=1.23 min

(269) MS (ES.sup.+): m/e=670.3 (M+H.sup.+)

(270) MS (ES.sup.−): m/e=668.5 (M−H), 714.6 (M+HCOO.sup.−)

Example 11b

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]propanoic acid

(271) ##STR00259##

(272) 225 mg (0.34 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 11 ml tetrahydrofurane and treated with 4.0 ml 0.1N sodium hydroxide solution. The mixture was stirred for 15 minutes and concentrated to give 220 mg (100%).

(273) UPLC (ACN-HCOOH): Rt.=1.15 min

(274) MS (ES.sup.+): m/e=656.4 (M+H.sup.+)

(275) MS (ES.sup.−): m/e=654.5 (M−H)

Example 11c

(3S)-3-[5-(4-Fluoro-3-nitrophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(276) ##STR00260##

(277) The mixture obtained in example 11b containing 220 mg (0.34 mmol) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-(4-fluoro-3-nitrophenyl)pyridin-3-yl]propanoic acid was dissolved in 20.5 ml dioxane. 0.84 ml (3.4 mmol) 4N hydrochloric acid were added. The mixture was stirred at room temperature for 20 hours and then concentrated. To the residue was added a little amount of water and saturated sodium hydrogen carbonate solution to get a pH=6. The mixture was concentrated and extracted with dichloromethane/2-propanol 8:2. The organic solutions were filtered and concentrated to give 213 mg, 211 mg of which were purified by HPLC:

(278) TABLE-US-00017 System: Dionex: Pump P 580, Gilson: Liquid Handler 215, Knauer: UV-Detektor K-2501 Column: Chiralcel OZ-H 5 μm 250 × 30 mm Solvent: Ethanol/Methanol 50:50 Flow: 30 mL/min Temperature: RT Solution: 211 mg/3 mL EtOH/MeOH 1:1 Injection: 4 × 0.75 mL Detection: UV 254 nm Fractions: Rt. in min DAD TAC Amount 11 5.4-7.1 83.6% 65 mg 12 10.4-12.2 90.8% 35 mg The fractions were concentrated and dried in the high vacuum.

(279) Fraction 12 contained the desired isomer.

(280) UPLC (ACN-HCOOH): Rt. =0.78 min

(281) MS (ES.sup.+): m/e=556.4 (M+H.sup.+)

(282) MS (ES.sup.−): m/e=554.4 (M−H)

Example 12

(3R)-3-{5-[(3-Cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-[({(3S)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(283) ##STR00261##

Example 12a

Tert-butyl 4-{3-[(3R)-3-[(1S)-1-{5-[(3-cyano-4-fluorobenzyl)oxy]pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(284) ##STR00262##

(285) Polymer bound triphenylphosphine (30 mg) and tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 5e, 30 mg, 60 μmol) were stirred in dichloromethane for 30 minutes. 2-Fluoro-5-(hydroxymethyl)benzonitrile (26 mg, 0.17 mmol) in THF was added and the mixture was cooled to 0° C. Dipropan-2-yl diazene-1,2-dicarboxylate (20 μL, 0.11 mmol) was added, the mixture was stirred for 3 hours at room temperature and then stored for 16 hours at 5° C. After filtration the filtrate was concentrated under reduced pressure and the residue was purified by preparative thin layer chromatography on silica gel (ethyl acetate 100%) to yield 3.2 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(3-cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(286) UPLC (ACN-HCOOH): Rt.=1.24 min

(287) MS (ES.sup.+): m/e=680.4 (M+H.sup.+)

(288) MS (ES.sup.−): m/e=724.5 (M+HCOO.sup.−).

Example 12b

(3R)-3-{5-[(3-Cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-[({(3S)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(289) Tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(3-cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (3.2 mg, 10 μmol) as solved in tert.-butanol (0.15 mL) and methanol (0.13 mL) and barium hydroxide octahydrate (7.4 mg, 20 μmol) was added. After stirring for 45 minutes at room temperature the solvent was distilled off at 0° C. by high vacuum. The residue was solved in water (0.3 mL) and acidified by formic acid (0.9 mL). After 3 hours at room temperature the solvent was distilled off at 0° C. by high vacuum and the residue was purified by preparative HPLC to yield 0.8 mg of (3R)-3-{5-[(3-cyano-4-fluorobenzyl)oxy]pyridin-3-yl}-3-[({(3S)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(290) TABLE-US-00018 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 5% B, 0.5-6 min 5-40% B, Flow: 150 mL/min Temperature: RT Detection: 284 nm Rt.: 368-4.04 min

(291) UPLC (ACN-HCOOH): Rt.=0.70 min

(292) MS (ES.sup.+): m/e=567.3 (M+H.sup.+)

(293) MS (ES.sup.−): m/e=565.3 (M−H).

Example 13

(3S)-3-{5-[(4-Cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(294) ##STR00263##

Example 13a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(4-cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(295) ##STR00264##

(296) To tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 5e, 200 mg, 0.37 mmol) in DMF (5 mL) was added sodium hydride (60%, 9.6 mg, 0.24 mmol) and the mixture was cooled to 0° C. 4-(Bromomethyl)-2-fluorobenzonitrile (70.5 mg, 0.33 mmol) in DMF (3 mL) was added while stirring and the mixture was warmed to room temperature. After one hour water, brine and ethyl acetate were added. Phases were separated and the aqueous phase was extracted with ethyl acetate. The combined extracts were dried over sodium sulfate and concentrated in vacuum. The residue was purified by preparative HPLC to yield 10 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-1-{5-[(4-cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(297) TABLE-US-00019 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 30% B, 0.5-7 min 30-70% B, Flow: 120 mL/min Temperature: RT Detection: 280 nm Rt.: 4.61-5.04 min

(298) UPLC (ACN-HCOOH): Rt.=1.22 min

(299) MS (ES.sup.+): m/e=680.4 (M+H.sup.+)

(300) MS (ES.sup.−): m/e=678.6 (M−H), 724.5 (M+HCOO.sup.−).

Example 13b

(3S)-3-{5-[(4-Cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(301) Tert-butyl 4-{3-[(3R)-3-{[(1S)-1-(5-(4-cyano-3-fluorobenzyloxy)pyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (10 mg, 15 μmol) as solved in tert.-butanol (0.6 mL) and methanol (0.6 mL) and barium hydroxide octahydrate (23 mg, 74 μmol) was added. After stirring for 45 minutes room temperature the solvent was distilled off at 0° C. by high vacuum. The residue was acidified with formic acid (1 mL). After 18 hours at 5° C. the solvent was distilled off at 0° C. by high vacuum and the residue was purified by preparative HPLC to yield 4 mg of (3R)-3-{5-[(4-cyano-3-fluorobenzyl)oxy]pyridin-3-yl}-3-[({(3S)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(302) TABLE-US-00020 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 10% B, 0.5-7 min 10-50% B, Flow: 150 mL/min Temperature: RT Detection: 280 nm Rt.: 2.87-3.15 min

(303) UPLC (ACN-HCOOH): Rt.=0.71 min

(304) MS (ES.sup.+): m/e=566.4 (M+H.sup.+)

Example 14

(3S)-3-(4-Cyano-3-fluorophenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(305) ##STR00265##

Example 14a

3-Amino-3-(4-cyano-3-fluorophenyl)propionic acid

(306) ##STR00266##

(307) 500 mg (3.35 mmol) 2-fluoro-4-formylbenzonitrile were suspended in 2 ml ethanol. 349 mg (3.35 mmol) propanedioic acid and 0.54 g (7.04 mmol) ammonium acetate were added. The mixture was refluxed for 6 hours and after cooling filtrated. The residue was washed with ethanol and dried in vacuum to give 360 mg (52%) 3-amino-3-(4-cyano-3-fluorophenyl)propionic acid.

Example 14b

3-Amino-3-(4-cyano-3-fluorophenyl)propionic acid methyl ester

(308) ##STR00267##

(309) 436 mg (2.09 mmol) 3-amino-3-(4-cyano-3-fluorophenyl)propionic acid were suspended in 8.5 ml methanol and the mixture cooled to 0° C. 0.23 ml (3.14 mmol) thionyl chloride were slowly added. The mixture was stirred at room temperature for 20 hours and concentrated. The residue was treated with saturated sodium hydrogen carbonate solution and extracted with dichloromethane. The organic part was dried with sodium sulfate and concentrated. Chromatography over silica gel (dichloromethane/ethanol 100/0-97/3-94/6) gave 245 mg (47%) 3-amino-3-(4-cyano-3-fluoro-phenyl)-propionic acid methyl ester.

(310) UPLC (ACN-NH3): Rt.=0.77 min

(311) MS (ES.sup.+): m/e=222.74 (M+H.sup.+)

Example 14c

(3S)-3-(4-Cyano-3-fluorophenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(312) ##STR00268##

(313) It was produced analogously to examples 2b-2e starting with example 17b to give 254 mg which were purified by HPLC:

(314) TABLE-US-00021 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: Kromasil C18 5 μm 150 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = Methanol Gradient: 0-1 min 10% B, 1-12 min 10-50% B Flow: 50 mL/min Temperature: RT Solution: 268 mg/3 mL DMSO/MeOH 1:1 Injection: 4 × 0.75 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount −21 6.6-7.4 96.7% 38 mg −23 8.2-9.8 95.4% 43 mg The fractions were concentrated.

(315) Fraction 23 contained the desired isomer.

(316) UPLC (ACN-HCOOH): Rt.=0.63 min

(317) MS (ES.sup.+): m/e=459.1 (M+H.sup.+)

(318) MS (ES.sup.−): m/e=457.3 (M−H)

Example 15

(3S)-3-(5-{[4-(2-Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(319) ##STR00269##

Example 15a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-fluoroethoxy)phenyl]ethynyl}pyridine-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(320) ##STR00270##

(321) To a degassed solution of tert-butyl 4-[3-((3R)-3-{[(1S)-1-(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate (example 27c, 100 mg, 150 μmol), copper iodide (3.5 mg, 20 μmol), tetrakis(triphenylphosphine)palladium(0) (17.7 mg, 20 μmol) and {[4-(2-fluoroethoxy)phenyl]ethynyl}(trimethyl)silane (73 mg, 310 μmol) in 1,2-dimethoxyethan (0.9 mL) and n-butyl amine (0.23 mL) was added a 1 M tetra-n-butyl ammonium fluoride solution in THF (200 μL) over 15 minutes at 80° C. After 20 additional minutes at 80° C. (36 mg, mmol) was added, the mixture was diluted with water after 20 minutes and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. The residue was purified by preparative HPLC to yield 43 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[4-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(322) TABLE-US-00022 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H.sub.2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 65% B, 0.5-7 min 65-85% B, Flow: 120 mL/min Temperature: RT Detection: 273 nm Rt.: 2.50-2.98 min

(323) UPLC (ACN-HCOOH): Rt.=1.43 min

(324) MS (ES.sup.+): m/e=735.5 (M+H.sup.+)

(325) MS (ES.sup.−): m/e=779.7 (M+HCOO.sup.−)

Example 15b

(3S)-3-(5-{[4-(2-Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(326) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[4-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (15.7 mg, 20 μmol) was heated to 60° C. in formic acid for 40 minutes. The solution was then concentrated in vacuum and the residue purified by preparative HPLC to yield 8.9 mg of (3S)-3-(5-{[4-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(327) TABLE-US-00023 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H.sub.2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 20% B, 0.5-7 min 20-40% B, Flow: 95 mL/min Temperature: RT Detection: 271 nm Rt.: 2.78-4.62 min

(328) UPLC (ACN-HCOOH): Rt.=0.83 min

(329) MS (ES.sup.+): m/e=579.3 (M+H.sup.+)

Example 16

(3S)-3-(5-{[3-(2-Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(330) ##STR00271##

Example 16a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(331) ##STR00272##

(332) To a degassed solution of tert-butyl 4-[3-((3R)-3-{[(1S)-1-(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate (example 27c, 100 mg, 15 mmol), copper iodide (4.4 mg, 23 μmol) and tetrakis(triphenylphosphine)palladium(0) (18 mg, 15 μmol) in DMF (0.4 mL) and n-butyl amine (0.23 mL) was added a solution of 1-ethynyl-3-(2-fluoroethoxy)benzene (50 mg, 0.31 mmol) in DMF (0.6 mL) over 60 minutes at 100° C. After additional 20 minutes at 100° C. the mixture was diluted with DMSO and purified by preparative HPLC to yield 90 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(333) TABLE-US-00024 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 65% B, 0.5-7 min 65-90% B, Flow: 120 mL/min Temperature: RT Detection: 277 nm Rt.: 2.95-3.50 min

(334) UPLC (ACN-HCOOH): Rt.=1.45 min

(335) MS (ES.sup.+): m/e=735.5 (M+H)

(336) MS (ES.sup.−): m/e=779.5 (M+HCOO.sup.−)

Example 16b

(3S)-3-(5-{[3-(2-Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(337) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (15.7 mg, 20 μmol) was heated to 60° C. in formic acid (1.5 mL) for 40 minutes. The solution was then concentrated in vacuum and the residue purified by preparative HPLC to yield 9.6 mg of (3S)-3-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(338) TABLE-US-00025 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 10% B, 0.5-7 min 10-50% B, Flow: 120 mL/min Temperature: RT Detection: 271 nm Rt.: 4.09-4.38 min

(339) UPLC (ACN-HCOOH): Rt.=0.91 min

(340) MS (ES.sup.+): m/e=579.4 (M+H.sup.+)

(341) MS (ES.sup.−): m/e=577.4 (M−H)

Example 17

(3S)-3-[5-Fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(342) ##STR00273##

Example 17a

3-Amino-3-(3-bromo-5-fluorophenyl)propionic acid

(343) ##STR00274##

(344) 4.72 g (23.25 mmol) 3-bromo-5-fluorobenzaldehyde were suspended in 10 ml ethanol. 2.42 g (23.25 mmol) propanedioic acid and 3.76 g (48.82 mmol) ammonium acetate were added. The mixture was refluxed for 5 hours and after cooling to room temperature filtrated. The residue was washed with cold ethanol and dried in vacuum at 30° C. to give 880 mg (13%) 3-amino-3-(3-bromo-5-fluorophenyl)propionic acid. The filtrate was concentrated and crystallized from ethanol to give further 706 mg (12%) 3-amino-3-(3-bromo-5-fluorophenyl)propionic acid.

(345) UPLC (ACN-HCOOH): Rt.=0.58 min

(346) MS (ES.sup.+): m/e=264.1 (M+H.sup.+)

(347) MS (ES.sup.−): m/e=262.1 (M−H)

(348) .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ=2.43 (d, 2H), 4.25 (t, 1H), 7.31 (d, 1H), 7.43 (dt, 1H), 7.50 (s, 1H) ppm.

Example 17b

3-Amino-3-(3-bromo-5-fluorophenyl)propionic acid methyl ester

(349) ##STR00275##

(350) 1.59 g (6.05 mmol) 3-amino-3-(3-bromo-5-fluorophenyl)propionic acid were suspended in 24.5 ml methanol and the mixture cooled to 0° C. 0.66 ml (9.08 mmol) thionyl chloride were slowly added. The mixture was stirred at room temperature for 20 hours and concentrated. The residue was treated with saturated sodium hydrogen carbonate solution and extracted with dichloromethane. The organic part was dried with sodium sulfate and concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 1.55 g (93%) 3-amino-3-(3-bromo-5-fluorophenyl)propionic acid methyl ester.

(351) UPLC (ACN-NH3): Rt.=1.02 min

(352) MS (ES.sup.+): m/e=278.1 (M+H.sup.+)

(353) .sup.1H-NMR (300 MHz, CHLOROFORM-d): δ=2.55-2.71 (m, 2H), 3.70 (s, 3H), 4.40 (dd, 1H), 7.06 (d, 1H), 7.15 (d, 1H), 7.33 (s, 1H) ppm.

Example 17c

Tert-butyl 4-{3-[(3R)-3-{[1-(3-bromo-5-fluorophenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(354) ##STR00276##

(355) 587.2 mg (2.13 mmol) 3-amino-3-(3-bromo-5-fluoro-phenyl)-propionic acid methyl ester were dissolved in 8.2 ml N,N-dimethylformamide and cooled to 0° C. To this solution was added a solution of 1100 mg (2.36 mmol) tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 5c) and 0.89 ml (6.38 mmol) triethylamine in 8.2 ml dichloromethane. The mixture was kept at 6° C. for 20 hours. Saturated ammonium chloride solution was added and the mixture extracted with dichloromethane. The organic layer was dried over sodium sulfate and concentrated in vacuum to give 1.66 g (125%) tert-butyl 4-{3-[(3R)-3-{[1-(3-bromo-5-fluorophenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate with 80% purity.

(356) UPLC (ACN-HCOOH): Rt.=1.35 min

(357) MS (ES.sup.+): m/e=628.5 (M+H.sup.+)

(358) MS (ES.sup.−): m/e=626.4 (M−H), 672.4 (M+HCOO.sup.−)

Example 17d

Tert-butyl 4-{3-[(3R)-3-{[(1-(5-fluoro-4′-hydroxybiphenyl-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(359) ##STR00277##

(360) To 558.0 mg (0.71 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(3-bromo-5-fluorophenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate in 17.4 ml toluene were added 16.5 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 117.9 mg (0.85 mmol) (4-hydroxyphenyl)boronic acid in 4.3 ml ethanol and 82.8 mg (1.43 mmol) potassium fluoride in 4.4 ml water. The mixture was stirred at 100° C. for 4 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 417 mg (92%) tert-butyl 4-{3-[(3R)-3-{[(1-(5-fluoro-4′-hydroxybiphenyl-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(361) UPLC (ACN-HCOOH): Rt.=1.24 min

(362) MS (ES.sup.+): m/e=640.5 (M+H.sup.+)

(363) MS (ES.sup.−): m/e=638.5 (M−H), 684.5 (M+HCOO.sup.−)

Example 17e

Tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(364) ##STR00278##

(365) 234 mg (0.37 mmol) tert-butyl 4-{3-[(3R)-3-{[(1-(5-fluoro-4′-hydroxybiphenyl-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 4.0 ml tetrahydrofurane. 238 mg (0.73 mmol) cesium carbonate and 120.9 mg (0.70 mmol) 1-iodo-2-fluoroethane were added. The mixture was stirred at room temperature for 20 hours. 120.9 mg (0.70 mmol) 1-iodo-2-fluoroethane were added and the mixture stirred at room temperature for 70 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 225 mg (90%) tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(366) UPLC (ACN-HCOOH): Rt.=1.38 min

(367) MS (ES.sup.+): m/e=686.2 (M+H.sup.+)

(368) MS (ES.sup.−): m/e=730.5 (M+HCOO.sup.−)

Example 17f

3-({[(3R)-1-{3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]propanoic acid

(369) ##STR00279##

(370) 220 mg (0.32 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate were dissolved in 10.4 ml tetrahydrofurane. 3.85 ml (0.39 mmol) 0.1N sodium hydroxide solution were added. The mixture was stirred at room temperature for 20 hours, diluted with water and a small amount of 1N sodium hydroxide solution and extracted with ethyl acetate. The aqueous layer was brought to pH=4.5 with 10% aqueous citric acid solution and extracted with dichloromethane and dichloromethane/2-propanol 8/2. The organic layer was dried over sodium sulfate and concentrated in vacuum to give 150 mg (70%) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]propanoic acid.

(371) UPLC (ACN-HCOOH): Rt.=1.32 min

(372) MS (ES.sup.+): m/e=672.3 (M+H.sup.+)

(373) MS (ES.sup.−): m/e=670.4 (M−H)

Example 17 g

(3S)-3-[5-Fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(374) ##STR00280##

(375) 148 mg (0.22 mmol) 3-({[(3R)-1-{3-[1-(tert-butoxycarbonyl)piperidin-4-yl]propanoyl}piperidin-3-yl]carbonyl}amino)-3-[5-fluoro-4′-(2-fluoroethoxy)biphenyl-3-yl]propanoic acid were suspended in 13.4 ml dioxane. 0.55 ml (2.20 mmol) 4 N hydrochloric acid were added. The mixture was stirred at room temperature for 20 hours and then concentrated to give 150 mg which were purified by HPLC:

(376) TABLE-US-00026 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.2% NH3 B = Methanol Gradient: 0-1 min 10% B, 1-12 min 10-80% B Flow: 50 mL/min Temperature: RT Solution: 150 mg/3 mL DMSO/MeOH 1:1 Injection: 3 × 1 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min DAD TAC Amount 11 8.4-8.8  >99% 41 mg 12 9.3-9.8 98.3% 18 mg The fractions were concentrated, mixed with tert.-butanol and lyophilized.

(377) Fraction 12 contained the desired isomer.

(378) UPLC (ACN-HCOOH): Rt.=1.12 min

(379) MS (ES.sup.+): m/e=572.19 (M+H.sup.+)

(380) MS (ES.sup.−): m/e=570.16 (M−H)

Example 18

(3S)-3-(5-{2-[4-(2-Fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(381) ##STR00281##

Example 18a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(382) ##STR00282##

(383) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (20 mg, 30 μmol) in ethyl acetate (0.8 mL) and methanol (013 mL) was stirred for 4.45 hours at room temperature under a hydrogen atmosphere in the presence of palladium on charcoal (10%, 19 mg). The suspension was filtrated through celite, which were washed thoroughly with methanol. The solution was concentrated under reduced pressure and purified by preparative HPLC to yield 13.9 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(384) TABLE-US-00027 Column: C18 Chromatorex 10 μm 125 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 40% B, 0.5-7 min 40-80% B, Flow: 120 mL/min Temperature: RT Detection: 271 nm Rt.: 3.48-4.35 min

(385) UPLC (ACN-HCOOH): Rt.=1.31 min

(386) MS (ES.sup.+): m/e=739.5 (M+H.sup.+)

(387) MS (ES.sup.−): m/e=783.4 (M+HCOO.sup.−)

Example 18b

(3S)-3-(5-{2-[4-(2-Fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(388) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[4-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (12.5 mg, 20 μmol) was heated to 60° C. in formic acid for 30 minutes. The solution was then concentrated in vacuum and the residue purified by preparative HPLC to yield 9.2 mg of (3S)-3-(5-{2-[4-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(389) TABLE-US-00028 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 10% B, 0.5-7 min 10-40% B, Flow: 120 mL/min Temperature: RT Detection: 269 nm Rt.: 2.31-3.41 min

(390) UPLC (ACN-HCOOH): Rt.=0.69 min

(391) MS (ES.sup.+): m/e=583.5 (M+H.sup.+)

Example 19

(3S)-3-(5-{2-[3-(2-Fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(392) ##STR00283##

Example 19a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(393) ##STR00284##

(394) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (30 mg, 40 μmol) in ethyl acetate (1.2 mL) and methanol (0.2 mL) was stirred for 2.5 hours at room temperature under a hydrogen atmosphere in the presence of palladium on charcoal (10%, 3 mg). The suspension was filtrated through celite, which were washed thoroughly with methanol. The solution was concentrated under reduced pressure and purified by preparative HPLC to yield 21.9 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(395) TABLE-US-00029 Column: C18 Chromatorex 10 μm 125 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 40% B, 0.5-7 min 40-80% B, Flow: 120 mL/min Temperature: RT Detection: 271 nm Rt.: 3.48-4.35 min

(396) UPLC (ACN-HCOOH): Rt.=1.31 min

(397) MS (ES.sup.+): m/e=739.5 (M+H.sup.+)

(398) and 2.4 mg of an E/Z mixture of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-fluoroethoxy)phenyl]ethenyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(399) UPLC (ACN-HCOOH): Rt.=1.38 min

(400) MS (ES.sup.+): m/e=737.5 (M+H.sup.+)

Example 19b

(3S)-3-(5-{2-[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(401) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (20 mg, 30 μmol) was heated to 60° C. in formic acid for 50 minutes. The solution was then concentrated in vacuum and the residue purified by preparative HPLC to yield 12 mg of (3S)-3-(5-{2-[3-(2-fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(402) TABLE-US-00030 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 10% B, 0.5-7 min 10-40% B, Flow: 120 mL/min Temperature: RT Detection: 269 nm Rt.: 2.27-3.48 min

(403) UPLC (ACN-HCOOH): Rt.=0.69 min

(404) MS (ES.sup.+): m/e=583.3 (M+H.sup.+)

Example 20

(E/Z)(3S)-3-(5-{2-[3-(2-Fluoroethoxy)phenyl]ethenyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(405) ##STR00285##

(406) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-({[3-(2-fluoroethoxy)phenyl]ethenyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (2.4 mg, 3.2 μmol) was heated to 60° C. in formic acid for 40 minutes. The solution was then concentrated in vacuum to yield 1.6 mg of (E/Z)(3S)-3-(5-{2-[3-(2-fluoroethoxy)phenyl]ethenyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid.

(407) UPLC (ACN-HCOOH): Rt.=0.75/0.77 min

(408) MS (ES.sup.+): m/e=581.5 (M+H.sup.+)

Example 21

Tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(409) ##STR00286##

(410) Tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 4e, 80 mg, 0.15 mmol) was dissolved in N,N-dimethylformamide (20 mL). Cesium carbonate (120 mg, 0.37 mmol) and ethylene glycol bis-p-toluenesulfonate (81 mg, 0.22 mmol) were added. The mixture was stirred at room temperature for 2 hours, quenched by addition of saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by preparative thin layer chromatography on silica gel (ethyl acetate in dichloromethane 60%) to yield 67 mg of tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat.

(411) UPLC (ACN-HCOOH): Rt.=1.39 min

(412) MS (ES.sup.+): m/e=744.60 (M+H.sup.+)

(413) MS (ES.sup.−): m/e=788.52 (M+HCOO.sup.−)

Example 22

Tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(414) ##STR00287##

(415) 100 mg (0.18 mmol) Tert-butyl 4-[3-((3R)-3-{[1-(4-hydroxyphenyl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate (example 2b) were dissolved in 7 ml N,N-dimethylformamide. 179 mg (0.55 mmol) cesium carbonate and 102 mg (0.28 mmol) ethylene glycol bis-p-toluenesulfonate were added. The mixture was stirred at room temperature for 48 hours and concentrated. The remainder was taken up with saturated ammonium chloride solution and ethyl acetate. The aqueous phase was extracted with 3×20 ml ethyl acetate. The extracts were dried over sodium sulfate and concentrated to yield 195 mg. Chromatography over 5 g silica gel (dichloromethane/ethanol 100/0-95/5) gave 95 mg (63%) tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(416) UPLC (ACN-HCOOH): Rt.=1.37-1.38 min

(417) MS (ES.sup.+): m/e=744.37 (M+H.sup.+)

(418) MS (ES.sup.−): m/e=788.34 (M+HCOO.sup.−)

Example 23

Tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(419) ##STR00288##

Example 23a

(S)-3-Amino-3-(4-hydroxyphenyl)propionic acid tert-butyl ester

(420) ##STR00289##

(421) 1.00 g (5.52 mmol) commercial 3-amino-3-(4-hydroxy-phenyl)-propionic acid were suspended in 20 ml tert-butyl acetate and the mixture cooled to 15° C. 0.90 ml (11.10 mmol) perchloric acid were slowly added and the mixture stirred at 20° C. for 1.5 hours. The solution was extracted with saturated sodium hydrogen carbonate solution. The aqueous layer was brought to pH=8 with sodium carbonate and extracted with ethyl acetate. The organic parts were combined, dried over sodium sulfate and concentrated to yield 1.0 g (60%) racemic 3-amino-3-(4-hydroxy-phenyl)-propionic acid tert-butyl ester. This was separated into the enantiomers by HPLC:

(422) TABLE-US-00031 System: 2x Labomatic Pumpe HD-3000, Labomatic AS-3000, Knauer DAD 2600, Labomatic Labcol Vario 4000 Plus Column: Chiralpak AD-H 5 μm 250 × 50 mm Solvent: Hexane/IPA 90:10 + 0.1% Diethylamine Flow: 100 mL/min Temperature: RT Solution: 1000 mg/10 mL EtOH Injection: 4 × 2.5 mL Detection: UV 230 nm Fractions: Rt. in min % Amount 11 8.98 98.7 232.6 mg 12 11.07 96.4 232.7 mg The fractions were concentrated.

(423) Fraction 12 contained the desired isomer.

(424) UPLC (ACN-NH3): Rt.=0.81 min

(425) MS (ES.sup.+): m/e=239.18 (M+H.sup.+)

(426) MS (ES.sup.−): m/e=236.18 (M−H), 282.18 (M+HCOO.sup.−)

(427) Optical rotation (P2000 Polarimeter, CHCl.sub.3): [α].sub.D=−13.6°+/−0.11° Literature: [α].sub.D=−8.5° (Tetrahedron: Asymmetry 18 (2007) 1554-1566, 3.6.72 Compound (S)-46)

Example 23b

4-(3-{(R)-3-[(S)-2-tert-Butoxycarbonyl-1-(4-hydroxy-phenyl)-ethylcarbamoyl]-piperidin-1-yl}-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester

(428) ##STR00290##

(429) 214.0 mg (0.90 mmol) (S)-3-amino-3-(4-hydroxy-phenyl)-propionic acid tert-butyl ester were dissolved in 3.5 ml N,N-dimethylformamide and cooled to 0° C. To this solution was added a solution of 466.4 mg (1.00 mmol) tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 5c) and 0.38 ml (2.71 mmol) triethylamine in 3.5 ml dichloromethane. The mixture was kept at 6° C. for 20 hours. Saturated ammonium chloride solution was added and the mixture extracted with dichloromethane. The organic layer was dried over sodium sulfate and concentrated in vacuum to give 820 mg. Chromatography over 5 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 539 mg (102%) 4-(3-{(R)-3-[(S)-2-tert-butoxycarbonyl-1-(4-hydroxy-phenyl)-ethylcarbamoyl]-piperidin-1-yl}-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester

(430) UPLC (ACN-HCOOH): Rt.=1.24 min

(431) MS (ES.sup.+): m/e=588.5 (M+H.sup.+)

(432) MS (ES.sup.−): m/e=586.6 (M−H), 632.6 (M+HCOO.sup.−)

Example 23c

Tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(433) ##STR00291##

(434) 270.0 mg (0.46 mmol) 4-(3-{(R)-3-[(S)-2-tert-butoxycarbonyl-1-(4-hydroxy-phenyl)-ethylcarbamoyl]-piperidin-1-yl}-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester were dissolved in 17.7 ml N,N-dimethylformamide. 449 mg (1.38 mmol) cesium carbonate and 255.3 mg (0.69 mmol) ethylene glycol bis-p-toluenesulfonate were added. The mixture was stirred at room temperature for 20 hours and concentrated. The remainder was taken up with saturated ammonium chloride solution and ethyl acetate. The aqueous phase was extracted with 3×20 ml ethyl acetate. The extracts were dried over sodium sulfate and concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 227 mg (63%) tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate which were purified by HPLC:

(435) TABLE-US-00032 System: Waters Autopurificationsystem: Pump 254, Sample Manager 2767, CFO, DAD 2996, ELSD 2424, SQD 3001 Column: XBrigde C18 5 μm 100 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = Acetonitrile Gradient: 0-1 min 30% B, 1-8 min 30-100% B Flow: 50 mL/min Temperature: RT Solution: 227 mg/2 mL DMSO/MeOH 1:1 Injection: 2 × 1 mL Detection: DAD scan range 210-400 nm MS ESI+, ESI−, scan range 160-1000 m/z ELSD Fractions: Rt. in min % Amount 11 6.6-7.0 >99 125 mg The fractions were concentrated, mixed with tert.-butanol and lyophilized.

(436) UPLC (ACN-NH3): Rt.=1.48 min

(437) MS (ES.sup.+): m/e=787.8 (M+H.sup.+)

(438) MS (ES.sup.−): m/e=784.6 (M−H), 830.6 (M+HCOO.sup.−)

Example 24

Tert-butyl 4-{3-[(3R)-3-({((1S)-3-methoxy-1-[5-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(439) ##STR00292##

(440) Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 5e, 200 mg, 0.37 mmol) was dissolved in N,N-dimethylformamide (25.3 mL). Cesium carbonate (298 mg, 0.92 mmol) and ethylene glycol bis-p-toluenesulfonate (203 mg, 0.55 mmol) were added. The mixture was stirred at room temperature for 2 hours and stored at 5° C. for 17 hours. The mixture was quenched by addition of saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by preparative thin layer chromatography on silica gel (ethyl acetate 100%) to yield 109 mg of tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat.

(441) UPLC (ACN-NH3): Rt.=1.26 min

(442) MS (ES.sup.+): m/e=745.6 (M+H.sup.+)

(443) MS (ES.sup.−): m/e=789.5 (M+HCOO.sup.−)

Example 25

Tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(444) ##STR00293##

Example 25a

5-(Benzyloxy)pyridine-3-carbonitrile

(445) ##STR00294##

(446) 3-(Benzyloxy)-5-bromopyridine (5.38 g, 20.4 mmol, Harrowven et al. Tetrahedron, 2001, 57, 4447-4454) in DMF (33 mL) was stirred with copper cyanide (2.9 g, 32.6 mmol) at 160° C. for 7 hours. Saturated aqueous sodium hydrogen carbonate solution and ethyl acetate was added and the formed suspension was stirred at 50° C. for 15 minutes. After filtration the liquid phases were separated. The precipitate was triturated with 10% DMF in ethyl acetate (500 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL) at 50° C. and filtration and phase separation were performed. The treatment of the precipitate with saturated aqueous sodium hydrogen carbonate solution and 10% DMF in ethyl acetate was repeated two times and the combined organic phases washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 65%) to yield 3.13 g 5-(benzyloxy)pyridine-3-carbonitrile.

(447) .sup.1H-NMR (300 MHz, CDCl.sub.3): δ=5.16 (s, 2 H), 7.35-7.55 (m, 6 H), 8.50 (d, 1 H), 8.58 (d, 1 H) ppm.

Example 25 b

Tert-butyl 3-amino-3-[5-(benzyloxy)pyridin-3-yl]prop-2-enoate

(448) ##STR00295##

(449) Diisopropylamine (12.8 mL, 91 mmol) was added at 0° C. to a 3M solution of ethyl magnesium bromide in diethyl ether (15 mL, 45 mmol) and additional diethyl ether (40 mL). After one hour at 0° C. t-butyl acetate was added and stirring was continued for 30 minutes. 5-(benzyloxy)pyridine-3-carbonitrile (2.9 g, 13.8 mmol) in diethyl ether (40 mL) was added at 0° C. After 2.5 hours at 0° C. saturated aqueous ammonium chloride solution was added. Phases were separated and the aqueous phase was extracted with diethyl ether. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 45%) to yield 1.95 g tert-butyl 3-amino-3-[5-(benzyloxy)pyridin-3-yl]prop-2-enoate.

(450) .sup.1H-NMR (300 MHz, CDCl.sub.3): δ=1.53 (s, 9 H), 4.89 (s, 1 H), 5.14 (s, 2 H), 7.33-7.48 (m, 6 H), 8.42 (m, 2 H) ppm.

Example 25c

Tert-butyl (3S)-3-amino-3-[5-(benzyloxy)pyridin-3-yl]propanoate

(451) ##STR00296##

(452) To chloro(1,5-cyclooctadien)rhodium(I) dimer (29 mg, 60 μmol) and (R)-(−)-1-[(S)-2-Di-tert.-butyl-phosphino)ferrocenyl]ethyldi-(4-trifluormethylphenyl)phosphine (81 mg, 120 μmol) under an argon atmosphere was added 2,2,2-trifluoroethanol (4 mL) and the solution was stirred for 40 minutes. To tert-butyl 3-amino-3-[5-(benzyloxy)pyridin-3-yl]prop-2-enoate (1.95 g 5.97 mmol) in degassed 2,2,2-trifluoroethanol (10 mL) in a pressure vessel was added the rhodium catalyst solution and the solution was stirred for 22 hours at 50° C. under hydrogen pressure of 10 bar. The addition of an identically prepared rhodium catalyst solution in 2,2,2-trifluoroethanol (4 mL) was repeated and stirring under 10 bar hydrogen pressure at 50° C. was continued for additional 16 hours. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 12 to 100% followed by methanol in ethyl acetate 0 to 15%) to yield 1.16 g of enantiomerically enriched tert-butyl (3S)-3-amino-3-[5-(benzyloxy)pyridin-3-yl]propanoate.

(453) .sup.1H-NMR (400 MHz, CDCl.sub.3): δ=1.43 (s, 9 H), 2.59 (d, 2 H), 4.42 (t, 1 H), 5.12 (s, 2 H), 7.32-7.50 (m, 6 H), 8.23 (s, 1 H), 8.29 (m, 1 H) ppm.

(454) Optical rotation (P2000 Polarimeter, CHCl.sub.3): [α].sub.D=−15.5° (c=1.0 g/100 mL CHCl.sub.3)

Example 25d

Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(455) ##STR00297##

(456) To tert-butyl (3S)-3-amino-3-[5-(benzyloxy)pyridin-3-yl]propanoate (1.15 g, 3.5 mmol) in DMF (13.4 mL) was added tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate and triethylamine (1.46 mL, 10.5 mmol) in dichloromethane (13.5 mL) at 0° C. After 3 hours the mixture was quenched by addition of saturated aqueous ammonium chloride solution, phases were separated and the aqueous phase was extracted with diethyl ether. Combined organic extracts were dried over sodium sulphate, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 20 to 100% followed by methanol in ethyl acetate 0 to 20%) to yield 1.76 g tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(457) .sup.1H-NMR (300 MHz, DMSO.sub.d6): δ=0.79-1.08 (m, 3 H), 1.38 (s, 9 H), 1.35 (s, 9 H), 1.49-1.75 (m, 9 H), 2.29 (m, 3 H), 2.59-2.77 (m, 5 H), 2.89-3.13 (m, 1 H), 3.68-3.83 (m, 1 H), 3.83-3.97 (m, 2 H), 5.07-5.27 (m, 1 H), 5.17 (s, 2H), 7.28-7.51 (m, 6 H), 8.12 (br. s, 1 H), 8.24 (br. s, 1 H), 8.39-8.55 (m, 1 H)

Example 25e

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-hydroxypyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(458) ##STR00298##

(459) Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-(benzyloxy)pyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (1.69 g, 2.49 mmol) in ethyl acetate (73 mL) and methanol (12 mL) was stirred for 20 hours at room temperature under a hydrogen atmosphere in the presence of palladium on charcoal (10%, 170 mg). The suspension was filtrated through celite, which were washed thoroughly with methanol. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (methanol in ethyl acetate 0 to 15%) to yield 1.37 g of Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-hydroxypyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(460) .sup.1H-NMR (400 MHz, DMSO.sub.d6, 80° C.): δ=0.85-1.09 (m, 2 H), 1.36 (s, 9 H), 1.41 (s, 9 H), 1.30-1.47 (m, 5 H), 1.55-1.72 (m, 4 H), 1.77-1.89 (m, 1 H), 2.29 (m, 3 H), 2.59-2.77 (m, 5 H), 2.89-3.13 (m, 1 H), 3.83-3.97 (m, 3 H), 5.03-5.25 (m, 1 H), 7.09 (t, 1 H), 7.88-8.09 (m, 2 H), 8.14 (d, 1 H), 9.55 (br., 1 H) ppm.

Example 25f

Tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(461) 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-hydroxypyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (200 mg, 0.34 mmol) were dissolved in N,N-dimethylformamide (39 mL). Cesium carbonate (277 mg, 0.85 mmol) and ethylene glycol bis-p-toluenesulfonate (188 mg, 0.51 mmol) were added. The mixture was stirred at room temperature for 4 hours, the addition of cesium carbonate (277 mg, 0.85 mmol) and ethylene glycol bis-p-toluenesulfonate (188 mg, 0.51 mmol) was repeated and stirring at 5° C. was continued for 17 hours. The mixture was quenched by addition of saturated aqueous ammonium chloride solution and extracted with diethyl ether and ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20% to 100% followed by dioxane in ethyl acetate 0 to 60%) to yield 207 mg of tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat.

(462) UPLC (ACN-NH2): Rt.=1.37 min

(463) MS (ES.sup.+): m/e=787.5 (M+H.sup.+)

(464) MS (ES.sup.−): m/e=785.5 (M−H), 831.5 (M+HCOO.sup.−)

Example 26

Tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[4-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(465) ##STR00299##

(466) 82.0 mg (0.13 mmol) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 7a) were dissolved in 5.1 ml N,N-dimethylformamide. 129 mg (0.40 mmol) cesium carbonate and 73.2 mg (0.20 mmol) ethylene glycol bis-p-toluenesulfonate were added. The mixture was stirred at room temperature for 20 hours and concentrated. The remainder was taken up with saturated ammonium chloride solution and ethyl acetate. The aqueous phase was extracted with 3×20 ml ethyl acetate. The extracts were dried over sodium sulfate and concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 64 mg (59%) tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(467) UPLC (ACN-HCOOH): Rt.=1.30 min

(468) MS (ES.sup.+): m/e=821.4 (M+H.sup.+)

(469) MS (ES.sup.−): m/e=819.6 (M−H), 865.5 (M+HCOO.sup.−)

Example 27

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(470) ##STR00300##

Example 27a

Tert-butyl 3-amino-3-[5-bromopyridin-3-yl]prop-2-enoate

(471) ##STR00301##

(472) Diisopropylamine (9.2 mL, 65 mmol) was added at 0° C. to a 3M solution of ethyl magnesium bromide in diethyl ether (10.9 mL, 32.7 mmol) and additional diethyl ether (20 mL). After one hour at 0° C. tert-butyl acetate (4.3 mL, 32.7 mmol) was added and stirring was continued for 30 minutes. 5-Bromopyridine-3-carbonitrile (2.0 g, 10.9 mmol) in diethyl ether (42 mL) was added at 0° C. After two hours at 0° C. saturated aqueous ammonium chloride solution was added. Phases were separated and the aqueous phase was extracted with diethyl ether. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 0 to 60%) to yield 1.12 g tert-butyl 3-amino-3-(5-bromopyridin-3-yl)prop-2-enoate.

(473) .sup.1H-NMR (400 MHz, DMSO-d.sub.6): δ=1.44 (s, 9 H), 4.77 (s, 1 H), 7.15 (br., 2 H), 8.22 (t, 1 H), 8.75 (d, 1 H), 8.76 (d, 1 H) ppm.

Example 27b

Tert-butyl (3S)-3-amino-3-(5-bromopyridin-3-yl)propanoate

(474) ##STR00302##

(475) To chloro(1,5-cyclooctadien)rhodium(I) dimer (39 mg, 80 μmol) and (R)-(−)-1-[(S)-2-di-tert.-butyl-phosphino)ferrocenyl]ethyldi-(4-trifluormethylphenyl)phosphine (108 mg, 160 μmol) under an argon atmosphere was added 2,2,2-trifluoroethanol (5.8 mL) and the solution was stirred for 40 minutes. To tert-butyl 3-amino-3-(5-bromopyridin-3-yl)prop-2-enoate (1.59 g 5.32 mmol) in degassed 2,2,2-trifluoroethanol (11.6 mL) in a pressure vessel was added the rhodium catalyst solution and the solution was stirred for 22 hours at 50° C. under hydrogen pressure of 11 bar. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 12 to 100% followed by methanol in ethyl acetate 0 to 15%) to yield 1.16 g of enantiomerically enriched tert-butyl (3S)-3-amino-3-[5-(benzyloxy)pyridin-3-yl]propanoate.

(476) .sup.1H-NMR (300 MHz, CDCl.sub.3): δ=1.43 (s, 9 H), 2.59 (d, 2 H), 4.42 (t, 1 H), 7.92 (t, 1 H), 8.58 (d, 1 H), 8.53 (d, 1 H) ppm.

(477) α=−17.6° (c=1.0 g/100 mL, CHCl.sub.3)

Example 27c

Tert-butyl 4-{3-[(3R)-3-({(1S)-1-[5-bromopyridin-3-yl]-3-tert-butoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(478) ##STR00303##

(479) To tert-butyl (3S)-3-amino-3-(5-bromopyridin-3-yl)propanoate (1.33 g, 4.42 mmol) in DMF (17 mL) was added tert-butyl 4-{3-[(3R)-3-{[(2,5-dioxopyrrolidin-1-yl)oxy]carbonyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 25c 2.54 g, 4.91 mmol) and triethylamine (1.85 mL, 13.2 mmol) in dichloromethane (17 mL) at 0° C. After 3 hours the mixture was quenched by addition of saturated aqueous ammonium chloride solution, phases were separated and the aqueous phase was extracted with diethyl ether. Combined organic extracts were dried over sodium sulphate, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 12 to 100% followed by methanol in ethyl acetate 0 to 15%) to yield 2.1 g of tert-butyl 4-[3-((3R)-3-{[(1S)-1-(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate.

(480) UPLC (ACN-HCOOH): Rt.=1.35 min

(481) MS (ES.sup.+): m/e=651.4/653.4 (M+H.sup.+)

Example 27d

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[4-hydroxyphenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(482) ##STR00304##

(483) To tert-butyl 4-[3-((3R)-3-{[(1S)-1-(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate (200 mg, 307 μmol) in toluene (7.5 mL) was added tetrakis(triphenylphosphine)palladium(0) (14 mg, 0.01 mmol), (4-hydroxyphenyl) boronic acid (55 mg, 399 μmol) in ethanol (1.87 mL) and potassium fluoride (55 mg, 0.61 mmol) in water (1.87 mL). The mixture was stirred at 100° C. for 4 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. the residue was purified by chromatography on silica gel (ethyl acetate in hexane, 12 to 100% followed by methanol in ethyl acetate 0 to 15%) to yield 156 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[4-hydroxyphenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(484) UPLC (ACN-HCOOH): Rt.=1.17 min

(485) MS (ES.sup.+): m/e=665.5 (M+H.sup.+)

(486) MS (ES.sup.−): m/e=663.5 (M−H), 709.5 (M+HCOO.sup.−)

Example 27e

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(487) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[4-hydroxyphenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (100 mg, 0.15 mmol) were dissolved in N,N-dimethylformamide (17.4 mL). Cesium carbonate (122 mg, 0.38 mmol) and ethylene glycol bis-p-toluenesulfonate (84 mg, 0.23 mmol) were added. The mixture was stirred at room temperature for 4 hours, the addition of cesium carbonate (122 mg, 0.38 mmol) and ethylene glycol bis-p-toluenesulfonate (84 mg, 0.23 mmol) was repeated and stirring at 5° C. was continued for 17 hours. The mixture was quenched by addition of saturated aqueous ammonium chloride solution and extracted with diethyl ether and ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20 to 100% followed by dioxane in ethyl acetate 0 to 60%) to yield 85 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(488) UPLC (ACN-NH3): Rt.=1.44 min

(489) MS (ES.sup.+): m/e=863.6 (M+H.sup.+)

(490) MS (ES.sup.−): m/e=861.5 (M−H).

Example 28

Tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-cyanophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(491) ##STR00305##

(492) To 100.0 mg (0.16 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 4 ml toluene were added 3.8 mg tetrakis(triphenylphosphine)palladium(0), 35.7 mg (0.20 mmol) (4-chloro-3-cyano-phenyl)boronic acid in 1.0 ml ethanol and 29.6 mg (0.51 mmol) potassium fluoride in 1.0 ml water. The mixture was stirred at 100° C. for 6 hours, diluted with water and saturated sodium hydrogen carbonate solution and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 44 mg (36%) Tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-cyanophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(493) UPLC (ACN-HCOOH): Rt.=1.27 min

(494) MS (ES.sup.+): m/e=668.6 (M+H.sup.+)

(495) MS (ES.sup.−): m/e=664.5 (M−H), 710.5 (M+HCOO.sup.−)

Example 29

Tert-butyl-4-{3-[(3R)-3-{[(1S-1-{5-[(3-bromo-4-cyanobenzyl)oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(496) ##STR00306##

(497) To tert-butyl-4-{3-[(3R)-3-{[(1S)-1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (100 mg, 0.18 mmol) in DMF (3 mL) was added sodium hydride (8 mg, 60% 0.2 mmol). The solution was cooled to 0° C. and 2-bromo-4-(bromomethyl)benzonitrile (55 mg, 0.2 mmol) while stirring. The mixture was warmed to room temperature and quenched by addition of water and ethyl acetate after 45 minutes. Phases were separated and the water phase was extracted with ethyl acetate. Combined organic extracts were concentrated in vacuum and the residue was purified by preparative HPLC to yield 46 mg of tert-butyl-4-{3-[(3R)-3-{[(1S)-1-{5-[(3-bromo-4-cyanobenzyl) oxy]pyridin-3-yl}-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(498) TABLE-US-00033 Column: C18 Chromatorex 10 μm 30 × 125 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0 0.5 min 30% B, 0.5-7 min 30-70% B Flow: 120 mL/min Temperature: RT Detection: 276 nm Rt.: 5.31-5.70 min

(499) UPLC (ACN-HCOOH): Rt.=1.27 min

(500) MS (ES.sup.+): m/e=740.3/742.3 (M+H.sup.+)

Example 30

Tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[3-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(501) ##STR00307##

(502) 98.0 mg (0.16 mmol) Tert-butyl 4-{3-[(3R)-3-({1-[5-(3-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 6a) were dissolved in 6.1 ml N,N-dimethylformamide. 154 mg (0.47 mmol) cesium carbonate and 87.4 mg (0.24 mmol) ethylene glycol bis-p-toluenesulfonate were added. The mixture was stirred at room temperature for 68 hours and concentrated. The remainder was taken up with saturated ammonium chloride solution and ethyl acetate. The aqueous phase was extracted with 3×20 ml ethyl acetate. The extracts were dried over sodium sulfate and concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 70 mg (49%) tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[3-(2-{[(4-methylphenyl) sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(503) UPLC (ACN-HCOOH): Rt.=1.33 min

(504) MS (ES.sup.+): m/e=821.3 (M+H.sup.+)

(505) MS (ES.sup.−): m/e=865.5 (M+HCOO.sup.−)

Example 31

Tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[2-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(506) ##STR00308##

(507) 108.0 mg (0.17 mmol) Tert-butyl 4-{3-[(3R)-3-({1-[5-(2-hydroxyphenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8d) were dissolved in 6.7 ml N,N-dimethylformamide. 170 mg (0.52 mmol) cesium carbonate and 96.4 mg (0.26 mmol) ethylene glycol bis-p-toluenesulfonate were added. The mixture was stirred at room temperature for 68 hours and concentrated. The remainder was taken up with saturated ammonium chloride solution and ethyl acetate. The aqueous phase was extracted with 3×20 ml ethyl acetate. The extracts were dried over sodium sulfate and concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-90/10) gave 55 mg (37%) tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[2-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(508) UPLC (ACN-HCOOH): Rt.=1.30 min

(509) MS (ES.sup.+): m/e=821.3 (M+H.sup.+)

(510) MS (ES.sup.−): m/e=865.5 (M+HCOO.sup.−)

Example 32

Tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(511) ##STR00309##

(512) To 171.5 mg (0.28 mmol) tert-butyl 4-{3-[(3R)-3-{[1-(5-bromopyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 8c) in 7 ml toluene were added 6.5 mg (0.01 mmol) tetrakis(triphenylphosphine)palladium(0), 68.0 mg (0.34 mmol) (4-chloro-3-nitro-phenyl)boronic acid in 1.7 ml ethanol and 50.7 mg (0.87 mmol) potassium fluoride in 1.7 ml water. The mixture was stirred at 100° C. for 60 hours, diluted with water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5-90/10) gave 100 mg (47%) tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-nitrophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(513) UPLC (ACN-HCOOH): Rt.=1.30 min

(514) MS (ES.sup.+): m/e=686.2 (M+H.sup.+)

(515) MS (ES.sup.−): m/e=730.4 (M+HCOO.sup.−)

Example 33

Tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(516) ##STR00310##

(517) 178.0 mg (0.28 mmol) 4-(3-{(R)-3-[1-(5-fluoro-4′-hydroxy-biphenyl-3-yl)-2-methoxycarbonyl-ethylcarbamoyl]-piperidin-1-yl}-3-oxo-propyl)-piperidine-1-carboxylic acid tert-butyl ester (example 17d) were dissolved in 10.7 ml N,N-dimethylformamide. 272 mg (0.84 mmol) cesium carbonate and 154.6 mg (0.42 mmol) ethylene glycol bis-p-toluenesulfonate were added. The mixture was stirred at room temperature for 70 hours and concentrated. The remainder was taken up with saturated ammonium chloride solution and ethyl acetate. The aqueous phase was extracted with 3×20 ml ethyl acetate. The extracts were dried over sodium sulfate and concentrated. Chromatography over 10 g silica gel (dichloromethane/ethanol 100/0-95/5) gave 167 mg which were further purified by HPLC to yield 27 mg (11%) tert-butyl 4-{3-[(3R)-3-({1-[5-fluoro-4′-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)biphenyl-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(518) UPLC (ACN-HCOOH): Rt.=1.47 min

(519) MS (ES.sup.+): m/e=838.4 (M+H.sup.+)

(520) MS (ES.sup.−): m/e=882.4 (M+HCOO.sup.−)

Example 34

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(521) ##STR00311##

Example 34a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(522) ##STR00312##

(523) To a degassed solution of tert-butyl 4-[3-((3R)-3-{[(1S)-1-(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate (400 mg, 0.61 mol), copper iodide (14 mg, 70 μmol), tetrakis(triphenylphosphine)palladium(0) (71 mg, 60 μmol) and 4-[(trimethylsilyl)ethynyl]phenol (234 mg, 1.23 mmol) in 1,2-dimethoxyethan (3.5 mL) and n-butyl amine (0.91 mL) was added a 1 M tetra-n-butyl ammonium fluoride solution in THF (800 μL, 0.8 mmol) over 60 minutes at 80° C. After 10 additional minutes at 80° C. the mixture was diluted with water after cooling to room temperature and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuum. The residue was purified by preparative HPLC to yield 338 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(524) TABLE-US-00034 Column: C18 YMC-ODS AQ 10 μm 51 × 200 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-1 min 65% B, 1-10 min 65-85% B, Flow: 150 mL/min Temperature: RT Detection: 276 nm Rt.: 7.36-8.67 min

(525) UPLC (ACN-HCOOH): Rt.=1.31 min

(526) MS (ES.sup.+): m/e=689.5 (M+H.sup.+)

Example 34b

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(527) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (60 mg, 0.09 mmol) was dissolved in N,N-dimethylformamide (10 mL). Cesium carbonate (71 mg, 0.22 mmol) and ethane-1,2-diyl bis(4-methylbenzenesulfonate (48 mg, 0.13 mmol) were added. The mixture was stirred at room temperature for 25 hours while the addition of cesium carbonate (71 mg, 0.22 mmol) and ethane-1,2-diyl bis(4-methylbenzenesulfonate (48 mg, 0.13 mmol) was repeated after 4 and 6 hours. The mixture was quenched by addition of saturated aqueous ammonium chloride solution and extracted with diethyl ether and ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20% to 100% followed by dioxane in ethyl acetate 0 to 50%) to yield 48 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(528) UPLC (ACN-HCOOH): Rt.=1.51 min

(529) MS (ES.sup.+): m/e=887.7 (M+H.sup.+)

Example 35

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(530) ##STR00313##

Example 35a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(531) ##STR00314##

(532) To a degassed solution of tert-butyl 4-[3-((3R)-3-{[(1S)-1-(5-bromopyridin-3-yl)-3-tert-butoxy-3-oxopropyl]carbamoyl}piperidin-1-yl)-3-oxopropyl]piperidine-1-carboxylate (example 27c, 300 mg, 0.46 mmol), copper iodide (13 mg, 70 μmol) and tetrakis(triphenylphosphine)palladium(0) (53 mg, 50 μmol) in DMF (1.5 mL) and n-butyl amine (0.68 mL) was added a solution of 3-ethynylphenol (103 mg, 0.88 mmol) in DMF (1.0 mL) over 35 minutes at 100° C. After 5 additional minutes at 100° C. the mixture was diluted with DMSO and purified by preparative HPLC to yield 289 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(533) TABLE-US-00035 Column: C18 YMC-ODS AQ 10 μm 51 × 200 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-1 min 65% B, 1-10 min 65-85% B, Flow: 240 mL/min Temperature: RT Detection: 276 nm Rt.: 7.86-9.09 min

(534) UPLC (ACN-HCOOH): Rt.=1.33 min

(535) MS (ES.sup.+): m/e=689.6 (M+H.sup.+)

Example 35b

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(536) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (40 mg, 0.06 mmol) was dissolved in N,N-dimethylformamide (6.7 mL). Cesium carbonate (47 mg, 0.15 mmol) and ethane-1,2-diyl bis(4-methylbenzenesulfonate (32 mg, 0.09 mmol) were added. The mixture was stirred at room temperature for 4 hours and stored for 72 hours at 5° C. The addition of cesium carbonate (47 mg, 0.15 mmol) and ethane-1,2-diyl bis(4-methylbenzenesulfonate (32 mg, 0.09 mmol) was repeated and the mixture was stirred at room temperature for 3 hours. The mixture was quenched by addition of saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20% to 100% followed by dioxane in ethyl acetate 0 to 50%) to yield 24 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(537) UPLC (ACN-HCOOH): Rt.=1.50 min

(538) MS (ES.sup.+): m/e=887.5 (M+H.sup.+)

Example 36

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(539) ##STR00315##

Example 36a

Tert-butyl 4-{3-[(3R)-3-{[(1 S)-3-tert-butoxy-1-{5-[2-(4-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(540) ##STR00316##

(541) Tert-butyl 4-{3-[(3R)-3-{[(1 S)-3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (190 mg, 0.28 mmol) in ethyl acetate (8.1 mL) and methanol (1.34 mL) was stirred for 4.45 hours at room temperature under a hydrogen atmosphere in the presence of palladium on charcoal (10%, 19 mg). The suspension was filtrated through celite, which were washed thoroughly with methanol. The solution was concentrated under reduced pressure and purified by preparative HPLC to yield 89 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[2-(4-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(542) TABLE-US-00036 Column: C18 YMC-ODS AQ 10 μm 51 × 200 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-1 min 40% B, 1-10 min 40-80% B, Flow: 240 mL/min Temperature: RT Detection: 276 nm Rt.: 4.40-4.74 min

(543) UPLC (ACN-HCOOH): Rt.=1.18 min

(544) MS (ES.sup.+): m/e=693.6 (M+H.sup.+)

Example 36b

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(545) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(4-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (67 mg, 0.10 mmol) was dissolved in N,N-dimethylformamide (9.7 mL). Cesium carbonate (79 mg, 0.24 mmol) and ethane-1,2-diyl bis(4-methylbenzenesulfonate) (54 mg, 0.15 mmol) were added. The mixture was stirred at room temperature for 4 hours, quenched by addition of saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20% to 100% followed by dioxane in ethyl acetate 0 to 60%) to yield 64 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(546) UPLC (ACN-NH3): Rt.=1.48 min

(547) MS (ES.sup.+): m/e=891.6 (M+H+)

Example 37

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-{[(4-methyl phenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(548) ##STR00317##

Example 37a

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(549) ##STR00318##

(550) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethynyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (200 mg, 0.29 mmol) in ethyl acetate (8.5 mL) and methanol (1.4 mL) was stirred for 7 hours at room temperature under a hydrogen atmosphere in the presence of palladium on charcoal (10%, 20 mg), while the addition of palladium on charcoal (10%, 20 mg) was repeated after 4 hours. The suspension was filtrated through celite, which were washed thoroughly with methanol. The solution was concentrated under reduced pressure and the residue was purified by preparative HPLC to yield 125 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[2-(3-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(551) TABLE-US-00037 Column: C18 Chromatorex 10 μm 125 × 30 mm Solvent: A = H2O + 0.1% HCOOH B = acetonitrile Gradient: 0-0.5 min 45% B, 0.5-6 min 45-70% B, Flow: 150 mL/min Temperature: RT Detection: 228 nm Rt.: 1.52-2.49 min

(552) UPLC (ACN-HCOOH): Rt.=1.19 min

(553) MS (ES.sup.+): m/e=693.5 (M+H.sup.+)

Example 37b

Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(554) Tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[(3-hydroxyphenyl)ethyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (67 mg, 0.10 mmol) was dissolved in N,N-dimethylformamide (9.7 mL). Cesium carbonate (79 mg, 0.24 mmol) and ethane-1,2-diyl bis(4-methylbenzenesulfonate (54 mg, 0.15 mmol) were added. The mixture was stirred at room temperature for 4 hours, quenched by addition of saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined extracts were washed with brine and dried over sodium sulfate. The solution was concentrated under reduced pressure and the residue was purified by chromatography on silica gel (ethyl acetate in hexane 20% to 100% followed by dioxane in ethyl acetate 0 to 50%) to yield 49 mg of tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate.

(555) UPLC (ACN-HCOOH): Rt.=1.43 min

(556) MS (ES.sup.+): m/e=891.5 (M+H+)

Example 38

(3S)-3-[3-(2-[18F]Fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(557) ##STR00319##
Radiosynthesis Via Direct Labeling:

(558) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then the diastereomeric mixture of tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylat (example 21, 2.0 mg, 2.69 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 10 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semiprep HPLC (Zorbax Bonus RP 5 μm C18-HL (9.4×250 mm), 17/83/0.1-acetonitrile/water/triflouro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[3-(2-[.sup.18F]fluoro-ethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 18.3-19.5 min; retention time of (3R)-3-[3-(2-[.sup.18F]fluoro-ethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}-carbonyl)amino]propanoic acid: 12.8-14.0 min). The collected fraction was diluted with 20 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL water). The cartridge was washed with 5 mL water and then the activity was eluted with 1.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) to get 73 to 297 MBq (3S)-3-[3-(2-[.sup.18F]fluoro-ethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}-carbonyl)amino]propanoic acid (radiochemical yield: 14±5.4% d.c.; synthesis time: 116±9.6 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 1) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, gradient: 5% B to 40% B in 7 min).

(559) Radiosynthesis Via Indirect Labeling:

(560) [.sup.18F]Fluoride was produced by an .sup.18O (p,n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetronitrile. 500 μL of o-dichlorobenzene (o-DCB) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 2 min in a sealed vial the vessel was cooled and then 4-nitro-benzenesulfonic acid 2-bromo-ethyl ester (10 mg, 32.24 μmol) was added. The resealed vial was heated again for 10 min at 130° C. Afterwards the reaction mixture was cooled again and two needles with tubings were sticked through Teflon membrane sealed reaction vial. One tubing is connected to a nitrogen flow regulator and the other tubing to a second vial equipped with 400 μL DMF. Using a constant small flow of nitrogen gas through the reaction mixture, this mixture was heated for additional 20 min at 100° C., while leading this nitrogen stream to the second vial where the nitrogen stream constantly bubbles through the 400 μL DMF. With the heating and the nitrogen stream the formed 2-[.sup.18F]fluoro-1-bromo-ethane in vial 1 is constantly driven to vial 2. After 20 min the distillation is stopped because no further increase of radioactivity in vial 2 could be detected.

(561) In a separate vial tert-butyl-4-{3-[(3R)-3-{[1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 4e, 2.50 mg, 4.58 μmol) was dissolved in 100 μL DMF. Then 2 M NaOH solution was added (20 μL, 40.0 μmol) and after standing for 1 min at 25° C. this mixture was added to vial 2 containing the 2-[.sup.18F]fluoro-1-bromo-ethane in 400 μL DMSO. The sealed vial 2 was heated for 25 min at 100° C. After cooling additional 100 μL 2 M NaOH was added to the reaction mixture and stirring was continued for 15 min at 25° C. The solution was acidified with 200 μL 4 M HCl and heated for 10 min at 100° C. in the sealed vial. The reaction mixture was neutralized with 4 M NaOH, diluted with 3 mL water and given on a semiprep HPLC (Zorbax Bonus RP 5 μm C18-HL (9.4×250 mm), 17/83/0.1-acetonitrile/water/triflouro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[3-(2-[.sup.18F]fluoro-ethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 13.4-14.7 min; retention time of (3R)-3-[3-(2-[.sup.18F]fluoro-ethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 8.6-9.7 min). The collected fraction was diluted with 20 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (100 μL) to get 10 to 15 MBq (3S)-3-[3-(2-[.sup.18F]fluoro-ethoxy)-phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 3±1.7% d.c.; synthesis time: 195±14.3 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 1) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, gradient: 5% B to 40% B in 7 min).

Example 39

(3S)-3-[4-(2-[18F]Fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(562) ##STR00320##

(563) [.sup.18F]Fluoride was produced by an .sup.18O (p,n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetronitrile. Then the diastereomeric mixture of tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 22, 2.0 mg, 2.69 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 10 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semiprep HPLC (Zorbax Bonus RP 5 μm C18-HL (9.4×250 mm), 19/81/0.1-acetonitrile/water/triflouro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[4-(2-[.sup.18F]fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 10.3-12.4 min; retention time of (3R)-3-[4-(2-[.sup.18F]fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 8.3-10.3 min). The collected fraction was diluted with 20 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) and sterile filtrated to get 115 to 151 MBq (3S)-3-[4-(2-[.sup.18F]fluoroethoxy)phenyl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 11±4.0% d.c.; synthesis time: 108±10.5 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 2) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, gradient: 5% B to 50% B in 7 min).

Example 40

(3S)-3-[5-(2-[18F]Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(564) ##STR00321##

Labeling of tert-Butyl 4-{3-[(3R)-3-({3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(565) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then the diastereomeric mixture of tert-butyl 4-{3-[(3R)-3-({3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 24, 2.0 mg, 2.68 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 10 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (Phenomenex Gemini 5 μm C18 110A (S/N: 337148-3; 10.0×250 mm), 10/90/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[5-(2-[.sup.18F]fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 15.1-17.0 min; retention time of (3R)-3-[5-(2-[.sup.18F]fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 8.0-8.4 min). The collected fraction was diluted with 40 mL water and given on a preconditioned Sep-Pak™ Plus C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) to get 113 to 168 MBq (3S)-3-[5-(2-[.sup.18F]fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 8.7±1.5% d.c.; synthesis time: 132±15.4 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 3) on an analytical HPLC (column: Phenomenex Gemini, C18 RP, 50×4.6 mm, 3 μ, 1.5 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 12% B for 7 min).

Labeling of tert-Butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(566) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-({(1S)-3-methoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 24, 2.0 mg, 2.68 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 10 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (Phenomenex Gemini 5 μm C18 110A (S/N: 337148-3; 10.0×250 mm), 10/90/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[5-(2-[.sup.18F]Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 15.4-18.4 min). The collected fraction was diluted with 40 mL water and given on a preconditioned Sep-Pak™ Plus C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) to get 127 to 435 MBq (3S)-3-[5-(2-[.sup.18F]Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 19.5±4.6% d.c.; synthesis time: 117±10 min). The radiochemical purity was >99% and the specific activity was between 38 and 107 GBq/μmol. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 3) on an analytical HPLC (column: Phenomenex Gemini, C18 RP, 50×4.6 mm, 3 μ, 1.5 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 12% B for 7 min).

Labeling of tert-Butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(567) [.sup.18F]Fluoride was produced by an .sup.18O (p,n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.28 mg Cs.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-({(1S)-3-tert-butoxy-1-[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-3-yl]-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 25, 4.0 mg, 5.08 μmol) in dry MeCN (400 μL) was added to the dried [.sup.18F]CsF-K.sub.222. After heating at 100° C. for 20 min in a sealed vial the vessel was cooled and 1 M HCl (400 μL) was added. The resealed vial was then again heated for 12 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (Phenomenex Gemini 5 μm C18 110A (S/N: 337148-3; 10.0×250 mm), 9/91/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[5-(2-[.sup.18F]Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 11.0-17.2 min). The collected fraction was diluted with 40 mL water and given on a preconditioned Sep-Pak™ Plus C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) to get 154 to 1351 MBq (3S)-3-[5-(2-[.sup.18F]Fluoroethoxy)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 21.3±5.9% d.c.; synthesis time: 126±20 min). The radiochemical purity was >99% and the specific activity was between 28.5 and 61.2 GBq/μmol. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 3) on an analytical HPLC (column: Phenomenex Gemini, C18 RP, 50×4.6 mm, 3μ, 1.5 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 12% B for 7 min).

Example 41

(3S)-3-{5-[4-(2-[18F]Fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(568) ##STR00322##

Labeling of tert-Butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(569) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then the diastereomeric mixture of tert-butyl 4-{3-[(3R)-3-{[3-methoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 26, 2.0 mg, 2.44 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 10 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 HL (10.0×250 mm), gradient (20 min): 20/80/0.1-35/65/0.1 acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-{5-[4-(2-[.sup.18F]fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 15.5-16.8 min; retention time of (3R)-3-{5-[4-(2-[.sup.18F]fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 13.2-15.4 min). The collected fraction was diluted with 40 mL water and given on a preconditioned Sep-Pak™ Plus C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) to get 65 to 163 MBq (3S)-3-{5-[4-(2-[.sup.18F]fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 9.0±1.0% d.c.; synthesis time: 128±1 0.0 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 7) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 15% B in 7 min).

Labeling of tert-Butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate

(570) [.sup.18F]Fluoride was produced by an .sup.18O (p,n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.28 mg Cs.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-{5-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]pyridin-3-yl}-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 27, 2.0 mg, 2.31 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]CsF-K.sub.222. After heating at 100° C. for 15 min in a sealed vial the vessel was cooled and 1 M HCl (150 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was neutralized with 1 M NaOH (150 μL) and diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 HL (10.0×250 mm), 21/79/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-{5-[4-(2-[.sup.18F]fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 13.0 min). The collected fraction was diluted with 30 mL water and given on a preconditioned Sep-Pak™ Plus C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (300 μL) to get 226 MBq (3S)-3-{5-[4-(2-[.sup.18F]fluoroethoxy)phenyl]pyridin-3-yl}-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 11% d.c.; synthesis time: 113 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 7) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 15% B in 7 min).

Example 42

(3S)-3-[5-(3-Cyano-4-[18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(571) ##STR00323##

(572) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.8 mg KHCO.sub.3 in 100 μL water and 10.4 mg K.sub.222 in 1.9 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then the diastereomeric mixture of 4-[3-((R)-3-{1-[5-(4-chloro-3-cyano-phenyl)-pyridin-3-yl]-2-methoxycarbonyl-ethylcarbamoyl}-piperidin-1-yl)-3-oxo-propyl]-piperidine-1-carboxylic acid tert-butyl ester (2.0 mg, 3.00 μmol) in dry DMSO (300 μL) was added to the dried [.sup.18F]KHF.sub.2—K.sub.222. After heating at 160° C. for 10 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 5 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 5 min at 70° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 HL (10.0×250 mm), gradient (20 min): 20/80/0.1-30/70/0.1 acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[5-(3-cyano-4-[.sup.18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 12.0-11.8 min; retention time of (3R)-3-[5-(3-cyano-4-[.sup.18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 10.0-10.5 min). The collected fraction was diluted with 30 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 0.7 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (200 μL) to get 12 to 111 MBq (3S)-3-[5-(3-cyano-4-[.sup.18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 4.0±1.0% d.c.; synthesis time: 125±19.8 min). The radiochemical purity was >99%. The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 9) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 15% B in 7 min).

Example 43

(3S)-3-[5-(4-Cyano-3-[18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(573) ##STR00324##

(574) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.8 mg KHCO.sub.3 in 100 μL water and 10.4 mg K.sub.222 in 1.9 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then the diastereomeric mixture of tert-butyl 4-{3-[(3R)-3-({1-[5-(4-chloro-3-cyanophenyl)pyridin-3-yl]-3-methoxy-3-oxopropyl}carbamoyl)piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 28, 1.0 mg, 1.87 μmol) in dry DMSO (300 μL) was added to the dried [.sup.18F]KHF.sub.2—K.sub.222. After heating at 160° C. for 15 min in a sealed vial the vessel was cooled and 0.5 M NaOH (100 μL) was added. Stirring was continued for 10 min at 25° C. before 1 M HCl (200 μL) was added. The resealed vial was then again heated for 10 min at 70° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 HL (10.0×250 mm), gradient (20 min): 20/80/0.1-30/70/0.1 acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-[5-(4-cyano-3-[.sup.18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 11.5-12.2 min; retention time of (3R)-3-[5-(4-cyano-3-[.sup.18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 9.9-10.8 min). The collected fraction was diluted with 15 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (100 μL) to get 7 to 38 MBq (3S)-3-[5-(4-cyano-3-[.sup.18F]fluorophenyl)pyridin-3-yl]-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 2.4±1.0% d.c.; synthesis time: 111±10.6 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 10) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 15% B in 7 min).

Example 44

(3S)-3-(5-{[4-(2-[18F]Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(575) ##STR00325##

(576) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.28 mg Cs.sub.2CO.sub.3 in 0.5 ml water and 5.25 mg K.sub.222 in 1.5 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 34, 2.0 mg, 2.25 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]CsF-K.sub.222. After heating at 100° C. for 15 min in a sealed vial the vessel was cooled and 1 M HCl (150 μL) was added. The resealed vial was then again heated for 12 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 (10.0×250 mm), 28/72/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-(5-{[4-(2-[.sup.18F]fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 17.8 min). The collected fraction was diluted with 15 mL water and given on a preconditioned Sep-Pak™Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (100 μL) to get 44 MBq (3S)-3-(5-{[4-(2-[.sup.18F]fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 5.0% d.c.; synthesis time: 139 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 15) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3 μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 20% B in 7 min).

Example 45

(3S)-3-(5-{[3-(2-[18F]Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(577) ##STR00326##

(578) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.28 mg Cs.sub.2CO.sub.3 in 500 μL water and 5.25 mg K.sub.222 in 1.5 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethynyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 35, 2.0 mg, 2.25 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]CsF-K.sub.222. After heating at 100° C. for 15 min in a sealed vial the vessel was cooled and 1 M HCl (150 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 HL (10.0×250 mm), 31/69/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-(5-{[3-(2-[.sup.18F]Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 14.9 min). The collected fraction was diluted with 15 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 0.5 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (100 μL) to get 63 MBq (3S)-3-(5-{[3-(2-[.sup.18F]Fluoroethoxy)phenyl]ethynyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 5.0% d.c.; synthesis time: 115 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 16) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3 μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 23% B in 7 min).

Example 46

(3S)-3-(5-{2-[4-(2-[18F]Fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(579) ##STR00327##

(580) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 36, 3.0 mg, 3.37 μmol) in dry MeCN (300 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 15 min in a sealed vial the vessel was cooled and 1 M HCl (150 μL) was added. The resealed vial was then again heated for 10 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (Phenomenex Synergi Hydro-RP 4 μm (250×10 mm), 18/82/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-(5-{2-[4-(2-[.sup.18F]fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 17.8 min). The collected fraction was diluted with 15 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (100 μL) and sterile filtrated to get 52 MBq (3S)-3-(5-{2-[4-(2-[.sup.18F]fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 5.5% d.c.; synthesis time: 145 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard on an analytical HPLC (column: Phenomenex Synergi Hydro, C18 RP, 50×4.6 mm, 4μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 18% B in 7 min).

Example 47

(3S)-3-(5-{2-[3-(2-[18F]Fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(581) ##STR00328##

(582) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (2.28 mg Cs.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 mL MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tert-butyl 4-{3-[(3R)-3-{[(1S)-3-tert-butoxy-1-(5-{2-[3-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)phenyl]ethyl}pyridin-3-yl)-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 37, 2.5 mg, 2.81 μmol) in dry MeCN (200 μL) was added to the dried [.sup.18F]CsF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled and 1 M HCl (150 μL) was added. The resealed vial was then again heated for 8 min at 100° C. After cooling the reaction mixture was diluted with 4 mL water and given on a semi prep HPLC (ACE 5 μm C18 HL (10.0×250 mm), 25/75/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-(5-{2-[3-(2-[.sup.18F]fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 13.2 min). The collected fraction was diluted with 15 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (200 μL) to get 290 MBq (3S)-3-(5-{2-[3-(2-[.sup.18F]fluoroethoxy)phenyl]ethyl}pyridin-3-yl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 19.1% d.c.; synthesis time: 88 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 19) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, gradient: 5% B to 50% B in 7 min).

Example 48

(3S)-3-(3-{2-[2-(2-[18F]Fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid

(583) ##STR00329##

(584) [.sup.18F]Fluoride was produced by an .sup.18O (p, n).sup.18F nuclear reaction by bombardment of a 98% .sup.18O-enriched water target with an 11MeVproton beam at the RDS111 cyclotron. The aqueous [.sup.18F]fluoride solution was trapped in a small anion exchange Sep-Pak™ Plus QMA cartridge (Waters) (preconditioned with 5 ml 0.5 M K.sub.2CO.sub.3 solution and 10 mL water). The radioactivity was eluted with a solution mixture (1.0 mg K.sub.2CO.sub.3 in 0.5 ml water and 5.27 mg K.sub.222 in 1.5 ml MeCN) from the QMA cartridge into a 5 mL conic Wheaton vial. The solvent was evaporated under a stream of nitrogen at 110° C. Azeotropic drying was repeated three times with 1.0 mL portions of acetonitrile. Then tri(ethylene glycol) di-p-toluenesulfonate (10 mg, 21.81 μmol) in dry MeCN (500 μL) was added to the dried [.sup.18F]KF-K.sub.222. After heating at 100° C. for 10 min in a sealed vial the vessel was cooled, diluted with 4 mL water and given on a semi prep HPLC ACE 5 μm C18 HL (10.0×250 mm), 50/50/0.1-acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of toluene-4-sulfonic acid 2-[2-(2-[.sup.18F]-fluoroethoxy)ethoxy]ethyl ester: 12.5 min). The collected fraction was diluted with 20 mL water and given on a preconditioned Sep-Pak™ Light C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 1.0 mL of MeCN. Afterwards the MeCN was completely evaporated at 90° C. under a slow stream of nitrogen gas to get the pure prosthetic group toluene-4-sulfonic acid 2-[2-(2-[.sup.18F]fluoroethoxy)ethoxy]ethyl ester (570 MBq).

(585) In a separate vial tert-butyl-4-{3-[(3R)-3-{[1-(5-hydroxypyridin-3-yl)-3-methoxy-3-oxopropyl]carbamoyl}piperidin-1-yl]-3-oxopropyl}piperidine-1-carboxylate (example 4e, 2.50 mg, 4.58 μmol) was dissolved in 300 μL DMF. Then 2 M NaOH solution was added (20 μL, 40.0 μmol) and after standing for 1 min at 25° C. this mixture was added to vial 1 containing the dried toluene-4-sulfonic acid 2-[2-(2-[.sup.18F]fluoroethoxy)ethoxy]ethyl ester. The sealed vial 2 was heated for 20 min at 100° C. After cooling additional 100 μL 1 M NaOH was added to the reaction mixture and stirring was continued for 10 min at 25° C. The solution was acidified with 200 μL 2 M HCl and heated for 10 min at 100° C. in the sealed vial. The reaction mixture was diluted with a 4 mL mixture of water/MeCN (1:1) and given on a semi prep HPLC ACE 5 μm C18 HL (10.0×250 mm), gradient (20 min): 15/85/0.1-50/50/0.1 acetonitrile/water/trifluoro acetic acid (volume-to-volume-to-volume ratio), 4 mL/min, retention time of (3S)-3-(3-{2-[2-(2-[.sup.18F]fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 28.3 min; retention time of (3R)-3-(3-{2-[2-(2-[.sup.18F]fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid: 29.0 min). The collected fraction was diluted with 20 mL water and given on a preconditioned Sep-Pak™ Plus C18 cartridge (preconditioned with 5 ml EtOH and 10 mL). The cartridge was washed with 5 mL water and then the activity was eluted with 2.0 mL of EtOH. After complete evaporation of the EtOH under a stream of nitrogen at 90° C. the final tracer was taken up in water (100 μL) to get 34 MBq (3S)-3-(3-{2-[2-(2-[.sup.18F]fluoroethoxy)ethoxy]ethoxy}phenyl)-3-[({(3R)-1-[3-(piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]propanoic acid (radiochemical yield: 4.5% d.c.; synthesis time: 172 min). The radiochemical purity was >99%. The F-18 labeled product was confirmed by co-injection with the F-19 cold standard (example 4) on an analytical HPLC (column: ACE, C18 RP, 50×4.6 mm, 3 μ, 2 ml/min (Agilent), solvent A: H2O+0.1% TFA, solvent B: MeCN+0.1% TFA, isocratic 20% B in 7 min).

Reference Compound

(3S)-3-[({(3R)-1-[3-(Piperidin-4-yl)propanoyl]piperidin-3-yl}carbonyl)amino]-3-{6-[3H]Pyridin-3-yl}propanoic acid

(586) ##STR00330##

(587) (3S)-3-(6-Bromopyridin-3-yl)-3-{[(3R)-1-(3-piperidin-4-yl-propanoyl)piperidine-3-carbonyl]amino}propanoic acid (1.85 mg, 3.73 μmol) was dissolved in a mixture of DMF (500 μL) and Et3N (25 μL). To this solution palladium on charcoal (20%) (6.45 mg) was added and the mixture was connected to a tritium manifold to tritiate over night with tritium gas. Afterwards the reaction mixture was 3 times cryostatically evaporated in the manifold. The obtained crude product was purified on a semi prep HPLC (Kromasil 100° C.8 5 μm (250×4.6 mm), eluent: 35 mM ammonia/methanol, flow: 1 mL/min). The collected fraction contained 2061 MBq (S)-3-{5-3H-pyridin-3-yl}-3-{[(R)-1-(3-piperidin-4-yl-propanoyl)-piperidin-3-carbonyl]-amino}-propanoic acid (radiochemical yield: 12.6%; radiochemical purity: 98%; specific activity: 7.81 Ci/mmol).

Example 49

(588) Affinities of GPIIb/IIIa Antagonists Towards Human GPIIb/IIIa Receptors

(589) The whole procedure of the used GPIIb/IIIa assay is schematic demonstrated in FIG. 1.

(590) Purified human glycoprotein IIb/IIIa (20 mM Tris-HCl, 0.1 M NaCl, 0.1% Triton X-100, 1 mM CaCl.sub.2, 0.05% NaN.sub.3, 50% Glycerol, pH 7.4) was purchased from Enzyme Research Laboratories Inc. (South Bend, Ind.). The GPIIb/IIIa receptor was diluted in phosphate-buffered saline (Dulbecco's Phosphate Buffered Saline (D-PBS (+)) with calcium and magnesium, GIBCO®, Invitrogen) with 0.01% bovine serum albumin (albumin from bovine serum-lyophilized powder, >96%, Sigma).

(591) The GPIIb/IIIa receptor was immobilized 48 hours at least (100 μL per well, 48 to maximum 96 hours) on a 96-well solid plate (Immuno Plate MaxiSorp™, Nunc, Roskilde, Denmark) at 277 K to 280 K and at a concentration of 0.1 μg per well to 1 μg per well. As negative control one row of the plate (n=8) was incubated just with 2% bovine serum albumin (200 μL per well, albumin from bovine serum-lyophilized powder, >96%, Sigma, diluted in D-PBS (+)).

(592) After washing three times with the wash buffer (230 μL per well, Dulbecco's Phosphate Buffered Saline (D-PBS (−)) contains no calcium or magnesium, GIBCO®, Invitrogen) residual exposed plastic and unspecific binding sites were blocked by incubating the plate with a special blocking solution (200 μL per well, Roti®-Block, Carl Roth GmbH Co KG, Karlsruhe) containing 2% bovine serum albumin (Albumin from bovine serum-lyophilized powder, >96%, Sigma) 1 hour at room temperature.

(593) After washing three times with the wash buffer 50 μL of tritiated reference compound (60 nM, .sup.3H-labeled compound) and 50 μL of novel compound (inhibitor, .sup.19F) were simultaneously added to each well and incubated for 1 hour at room temperature. Several concentrations of each novel inhibitor (0.1, 1, 2, 5, 10, 20 50, 100, 200, 500, 1000, 2000, 5000, 10000 and 20000 nM) were investigated. At each concentration of inhibitor a fourfold determination was performed. The results for the examined inhibitors are summarized in table 1.

(594) The maximum value of tritiated reference compound was determined without addition of inhibitor (n=8). To exclude unspecific binding of .sup.3H— reference compound wells without glycoprotein receptors were used as negative controls (n=12, identically treated just without GPIIb/IIIa receptors).

(595) After one hour the plate was washed three times with phosphate-buffered saline (200 μL per well, Dulbecco's Phosphate Buffered Saline (D-PBS (+)), GIBCO®, Invitrogen). Following 140 μL of liquid scintillation cocktail (MicroScint™ 40 aqueous, Perkin Elmer) was added to each well. After 15 min at room temperature the plates were measured at the microplate scintillation counter (TopCount NXT v2.13, Perkin Elmer, Packard Instrument Company).

(596) FIG. 1 shows a schematic diagram of GPIIb/IIIa assay. In the first step human glycoprotein IIb/IIIa, which is purified from human platelets, was immobilized on a 96-well solid plate. After 48 hours at least the plates were washed and the unspecific binding sites were blocked with Roti®-Block. In the next step, the plates were simultaneously incubated with a tritium labeled reference compound and the novel small molecule compound (inhibitor). The higher the affinity of the inhibitor, the smaller is the bound fraction of reference compound. The fraction of tritiated reference compound, which is not displaced by inhibitor, was measured at a microplate scintillation counter.

(597) The results are summarized in table 1.

(598) TABLE-US-00038 TABLE 1 Binding affinity of compounds towards human GPIIb/IIIa receptor. IC.sub.50 human Example [nM] 1 101 2 29 3 20 4 84 5 16 6 16 7 11 8 14 9 21 10 15 11 14 12 8 13 7 14 15 15 5 16 6 17 35 18 3 19 3 20 7

(599) The higher the affinity of the inhibitor, the smaller is the bound fraction of tritium-labeled reference compound. By means of this assay the active diastereomers identified and the affinities (IC50 values) could be determined. The studies described above indicate that compounds of formula I are useful as contrast agents for the imaging of thrombi. The good correlation between IC50-values and the actual thrombus accumulation are described in Example 50.

Example 50

(600) Ex Vivo Characterization

(601) Binding to Human Thrombi:

(602) The binding of compounds to thrombi was further investigated in an ex vivo blood flow model similar to that described in “Wakhloo, A. K. et al. Thrombus and stroke 2008, in vitro models 57-66” but modified with regard to thrombus development. Briefly, an open handmade tube-set consisting of tygon-tubes (Tygon R-1000, part No AAU00007: I.D. 3.2 mm, O.D. 6.4 mm, Saint Gobain Performance Plastics North America), intermediate tubes (Intrafix® Infusion set, B. Braun, Melsungen, Germany) an open reservoir (10 mL Combitip, Eppendorf) and a chamber made of a piece of polyethylene-Tube, (INTRAMEDIC Polyethylene Tubing, Clay Adams, PE160, length: 6.5 cm) containing a loop of a roughened thread (fishing line: Okuma UltraMax whitefish, diameter: 0.14 mm, length: 5 cm; sandpaper: CAMI Grit designation: 600, CP918a, VSM) was used for thrombus formation. The connection between the intermediate tube and the thrombus chamber was made by trimmed tips (epTIPS, 200 μL, Eppendorff, Hamburg/Germany). The Reservoir and the thrombus chamber were fixed by clamps and stands. A peristaltic-pump (Minipuls 3, Gilson, Middelton/USA) was used to pump the blood around thereby adjusting the flow in the middle of the thrombus chamber to 70-90 cm per second, which was monitored by ultrasound Doppler measurement (Vevo 770 High-Resolution In Vivo Micro-Imaging System, VisualSonics, Toronto/Ontario, Canada; Scanhead: RMV 704, 40 MHz). The volume of the entire tube-set was 7.5 or 15 mL.

(603) For each experiment fresh blood was taken from a volunteer using 10 mL citrate-tubes (Sarstedt S-Monovette 02.1067.001, 10 mL, Citrate 3.13%) and immediately laid into the turning-device of an incubator at a temperature of 37° C. (Heraeus miniTherm CTT with integrated rotation- and turning device, turning speed: 19 rotations per minute, Heraeus Instruments GmbH, Hanau/Germany). As needed, two tubes were taken out of the turning-device and 15 mL were transferred to a 20 mL Syringe (Omnifix®, B. Braun, Melsungen/Germany) and gently mixed with 0.75 mL CaCl.sub.2—Solution before the peristaltic pump was started and the whole content of the syringe was transferred into the reservoir of the tube-set via a cell strainer (BD Falcon™ cell strain, 40 μm, BD, Franklin Lakes, N.J. USA). After 7 minutes 1 MBq or 0.5 MBq (15 mL or 7.5 mL) of the compound was added to the reservoir by means of a pipette, thereby mixing the content gently with the tip of the pipette. The blood was left circulating for another 3 minutes. Then, the pump was stopped, aliquots were taken from the blood and the thrombus together with the roughened thread was removed from the thrombus-chamber before both was weighted and measured in a gamma counter (Automatic Gamma Counter Wizard.sup.2 3, Perkin Elmer). Then the thrombus together with the thread was incubated in Plasmin-solution (Plasmin from Human Plasma, Sigma Aldrich, stock-solution: 500 μg in 500 μL 150 μM Tris-buffer (pH 7.8), 20 μL stock-solution to 230 μL saline solution 0.9%) for 48 hours to separate the platelets from the thread and to determine the netto weight of the thrombus. Finally the activity of the compound in blood and thrombus as well as the ratio between both was determined (cpm/weight [mg]). The results for the investigated compounds are summarized in table 2.

(604) TABLE-US-00039 TABLE 2 In vitro clot-to-blood ratios and corresponding IC.sub.50-values Example # IC.sub.50 Example # in vitro clot-to- corresponding human .sup.18F-compound blood ratio* .sup.19F-compound [nM] 38 19 ± 1 (n = 9) 1 101 39 34 ± 4 (n = 4) 2 29 40 71 ± 4 (n = 3) 3 20 41  83 ± 14 (n = 6) 7 11 42  58 ± 10 (n = 6) 9 21 46 191 ± 30 (n = 4) 18 3 47 178 ± 48 (n = 4) 19 3 *Ratio of in vitro clot-to-blood ± standard error of the mean (SEM) 3 minutes post-injection of .sup.18F-labeled compound in the described in vitro thrombus model.

(605) To verify the specificity of the compound, a competition experiment was conducted in which the cold compound was added to the reservoir together with the hot compound. The final plasma concentration of the cold compound was 2.8 μM. The results are summarized in the table 3.

(606) TABLE-US-00040 TABLE 3 Competition experiments Accumulation Thrombus Thrombus competition Example # [10.sup.3 cpm/mg]* [10.sup.3 cpm/mg]* 38  41 ± 3 (n = 5) 10 ± 1 (n = 5) 39  86 ± 9 (n = 6) 12 ± 1 (n = 6) 40 202 ± 11 (n = 3)  8 ± 1 (n = 3) 41  44 ± 7 (n = 6)  5 ± 1 (n = 5) 42  39 ± 5 (n = 6)  5 ± 1 (n = 6) 46 285 ± 76 (n = 4) 17 ± 1 (n = 4) 47 258 ± 59 (n = 4) 14 ± 2 (n = 3) *Values ± standard error of the mean (SEM) 3 minutes post-injection of .sup.18F-labeled compound in the described in vitro thrombus model.

(607) The competition experiments showed that the accumulation of the tracer can be displaced by addition of the cold compound and verify that the binding is specific.

(608) The strong specific binding of the compounds to thrombi shown in table 2 and 3 (in vitro clot-to-blood ratio) correlates well to the IC.sub.50-values determined before (FIG. 2 and Example 49). The accumulation of compounds within thrombi or the clot-to-blood ratios grows with increasing affinity.

Example 51

(609) Plasma Protein Binding

(610) The determination of the plasma protein binding of compounds was performed by means of an equilibrium dialysis in a 96-well HT plate. Solutions of test compound (0.3 μM and 3 μM) were prepared in buffer (50 mM phosphate buffer) and 10% plasma. A 96 well HT dialysis plate (Teflon) was assembled so that each well was divided in two compartments by a semi-permeable cellulose membrane (regenerated Cellulose, MWCO 12-14K). The phosphate buffer solution (150 μL) was added to one side of the membrane and the plasma solution to the other side (150 μL). The compounds were added to the plasma solution side and were incubated at 37 degree. The unbound fraction of the compound could pass through the membrane and equilibrium between the two sides could be reached (6-8 h, 37° C.). Both solutions were analyzed for each compound (plasma-free and plasma-containing) by LC-MS. Both solutions for each compound were diluted with buffer or plasma to reach the same matrix (10% plasma) for analysis and were precipitated by the addition of methanol. The fraction unbound (Fu) was calculated as the quotient of the equilibrium concentrations of the compound in plasma-free and plasma-containing solution.

(611) The results are summarized in table 4. The extent of plasma protein binding has been investigated in human and monkey. Examples showed no significant binding to plasma proteins, with a fraction unbound (Fu) greater than 10% in all investigated species.

(612) TABLE-US-00041 TABLE 4 Plasma protein binding in human and monkey plasma at a concentration of 0.3 μM and 3 μM Example # Species Strain Concentration (μM) Fu (Mari) % 1 Human Caucasian 3 90 1 Human Caucasian 0.3 91 1 Monkey Cynomolgus 3 93 1 Monkey Cynomolgus 0.3 99 3 Human Caucasian 3 100 3 Human Caucasian 0.3 96 3 Monkey Cynomolgus 3 100 3 Monkey Cynomolgus 0.3 100 7 Human Caucasian 3 54 7 Human Caucasian 0.3 50 7 Monkey Cynomolgus 3 58 7 Monkey Cynomolgus 0.3 54

Example 52

(613) In Vitro Metabolic Stability in Liver Microsomes

(614) Human liver microsomes in suspension (protein content 0.5 mg/mL) were used for metabolic stability studies. The incubation concentration was 0.3 μM. The hole incubation volume was 3.03 mL in which 2.4 mL of a microsome suspension in phosphate buffer (7.4 pH) was activated by addition of 0.6 mL of a NADPH regeneration system (cofactor mixture: 1.2 mg NADP, 3 IU Glucose-6-Phosphat Dehydrogenase, 14.6 mg Glucose-6-Phosphat und 4.9 mg MgCl2 in phosphate buffer, pH 7.4). After addition of 30 μL of test compound the assay was started. The compound was dissolved in an organic solvent and diluted with the same liver microsome medium in order to keep the organic content below the recommended concentration (dimethylsulfoxide DMSO <0.2% and methanol <1%). The suspension was incubated at 37 degree for 60 minutes under continuous stirring (Tec Control Shaker RS 485 at 300 UpM). At different time points (2, 8, 16, 30, 45 and 60 min) 250 μL aliquots were taken and mixed with cold methanol. The samples were frozen over night at −20° C. The solutions were centrifuged for 15 min at 3000 g. The clear supernatant (100 μL) was used to determine the concentration. The analysis was performed with an Agilent 1200 HPLC system with a LCMS/MS detector.

(615) The susceptibility of investigated compounds to degradation by phase-I oxidative metabolism was investigated using liver microsomes from different species. Compound 1 and 3 revealed very high metabolic stability in human, monkey and rat (calculated CL.sub.blood=0.0001 L/h/kg). The recovery was almost 100% for all investigated species. Extrapolation of the in vitro to in vivo clearance (Clint) suggests a very low metabolic clearance in human, mouse, rat and monkey.

(616) TABLE-US-00042 TABLE 5 In vitro metabolic stability in human, monkey, rat and mouse microsomes Example # Species Strain Sex CL.sub.blood (L/h/kg) 1 Human Caucasian mix 0.0001 1 Monkey Cynomolgus female 0.0001 1 Rat Wistar male 0.0001 3 Human Caucasian mix 0.0001 3 Monkey Cynomolgus female 0.0001 3 Rat Wistar male 0.0001 3 Mouse NMRI female 0.0001

Example 53

(617) Pharmacokinetics in Mice

(618) The biodistribution of the compound described in example 41 was determined in nude mice. Briefly, the mice received 185 KBq of the compound each. At different time points (1, 3, 10, 30, 120 minutes p.i., 3 mice per group) the animals were sacrificed and the organs of interest or aliquots thereof were removed, weighted and finally measured in a gamma counter (Automatic Gamma Counter Wizard.sup.2 3, Perkin Elmer).

(619) The compound was rapidly eliminated from the blood and there was no enhancement in the vessel-wall. The compound was quickly excreted over the kidney and liver and there was almost no background in the whole rest of the body after 15 minutes p.i. (FIG. 3).

Example 54

(620) Blood Clearance in a Cynomolgus Monkey

(621) The blood clearance of the compound described in example 40 has been determined in a cynomolgus monkey. A female cynomolgus monkey was anesthetized with a mixture of Xylazin (Rompun®, Bayer HealthCare, Leverkusen, Germany), 0.12 mL/kg bodyweight and Ketamine (Ketavet®, Pfizer) 0.12 mL/kg bodyweight i.m. The monkey was placed inside the PET-scanner (Inveon PET/CT, Siemens Medical, Erlangen) and 25 MBq of the compound has been injected i.v. while PET-imaging was performed continuously from shortly before up to 60 minutes post injection. Venous blood samples were taken at 3, 10, 30 and 60 minutes p.i. and were measured in a gamma-counter (Automatic Gamma Counter Wizard.sup.2 3, Perkin Elmer). Additionally, the blood-concentration of the compound was measured from the PET-Image over the whole imaging period (FIG. 4).

(622) It was found that the compound described in example 40 was rapidly cleared from the blood. There was only marginal signal visible in any other tissue. The brain was completely free of contrast.

(623) This result correlates well with the results from the pharmacokinetic study in mice and underlines again the advantageous pharmacokinetic profile of the compound. Moreover, it shows that there is also no cross reaction to any other structures (e.g. integrines) at the healthy endothelium.

Example 55

(624) Thrombus-Imaging in Cynomolgus Monkeys

(625) The ability of the compound described in example 40 for the imaging of thrombi was investigated in a PET-study with cynomolgus monkeys (female, 2.8-3.2 kg).

(626) Monkey 1:

(627) The first monkey was anesthetized with a mixture of Xylazin (Rompun®, Bayer HealthCare, Leverkusen, Germany), 0.12 mL/Kg and Ketamine (Ketavet®, Pfizer) 0.12 mL/Kg b.w. i.m. and additionally analgesized by an i.m. injection of 6 μg Buprenorphine per kg. While the investigation, small amounts of Ketamine have been injected i.m. if required. The left common carotid artery was exposed surgically and a polyethylene-tube (INTRAMEDIC Polyethylene Tubing, Clay Adams, PE50), which was roughened previously by sandpaper (600—CAMI Grit designation), was inserted into the vessel, advanced into the descending aorta and was left there for 30 minutes to allow for the development of a thrombus on the rough surface of the tube. Meanwhile, the monkey was placed inside the PET-scanner (Inveon PET/CT, Siemens Medical, Erlangen). Then the monkey received 25 MBq of the compound i.v. and a PET-scan was taken from shortly before up to 60 minutes post injection. The image revealed a bright signal inside the descending aorta alongside the roughened part of the tube (FIG. 5), while there was only sparse signal in any tissue around the tube. Surprisingly there was only a very thin layer of thrombus covering the rough part of the tube visible after removal of the roughened tube from the animal. The thickness of this layer was far below 1 mm (see also removed thrombus of Monkey 2, FIG. 7) and therewith also far below the resolution of the image, which is approximately 1 mm. This also means, that even slightest thrombi, even if their size is far less than the resolution of the imaging-device, can be visualized due to the massive accumulation of compound on the platelets of the thrombi.

(628) At the end of the experiment the tube was removed carefully from the vessel before it was weighted and measured in a gamma counter (Automatic Gamma Counter Wizard.sup.2 3, Perkin Elmer). Then the thrombus together with the tube was incubated in Plasmin-solution (Plasmin from Human Plasma, Sigma Aldrich, Plasmin-stock-solution: 500 μg Plasmin in 500 μL Tris-buffer (150 μM, pH 7.8), 20 μL Plasmin-stock-solution to 230 μL saline solution 0.9%) for 48 hours to separate the platelets from the tube and to determine the netto weight of the thrombus. Finally the activity of the compound in blood and thrombus as well as the ratio between the two was determined (cpm/weight [mg]).

(629) Monkey 2:

(630) The experiment was repeated with the same compound in another monkey with a slightly different preparation of the thrombogenic tube: This tube was roughened at only two short sections with a gap in between. Apart from that, the experimental design including the determination of the in vivo clot-to-blood ratio was as described above for monkey 1.

(631) Unlike the thrombus of the first monkey now found two separate strong signals showed up in the PET image with a gap in between (FIG. 6). After removing the thrombogenic tube from the vessel, two separate thrombi could be found at the roughened parts of the tube (FIG. 7) proving that the signals were solely deriving from thrombus and not from the tube alone. As already known from monkey 1, these two thrombi were also extremely thin (FIG. 7).

(632) Monkey 3, Dose Reduction & Venous Thrombus

(633) The experiment was repeated with the same compound in another monkey, but with the reduced dose of 15 MBq for the whole animal. In addition to the arterial catheter, this animal also received a venous catheter, also made of PE50-catheter-tube and roughened at some parts with gaps in between as described above. This catheter was inserted into the left femoral vein and advanced into the upper caval vein. Both catheters were left in the vessels for 30 minutes before the compound was injected intravenously. PET imaging was performed from shortly before to 60 minutes after injection.

(634) As in the other monkeys, all arterial and venous thrombi showed a bright signal in the image (FIG. 8). As before, most of the signal was vanished from the blood and other tissues around the thrombi within some minutes.

(635) Clot-to-Blood Ratio In Vivo:

(636) The in vivo clot-to-blood ratio was determined from 5 thrombi out of the above described monkey experiments. As already mentioned above the thrombi had been removed from the vessels after imaging and had been weighted and measured in a gamma-counter (Automatic Gamma Counter Wizard.sup.2 3, Perkin Elmer) together with blood samples taken from the animal. After incubation of the thrombi in Plasmin (Plasmin from Human Plasma, Sigma Aldrich, Plasmin-stock-solution: 500 μg Plasmin in 500 μL Tris-buffer (150 μM, pH 7.8), 20 μL Plasmin-stock-solution to 230 μL saline solution 0.9%) and removal of the thrombi from the catheter tubes, the netto weight of the thrombi was calculated and the concentration of the compound in thrombus (clot) and blood, as well as the ratio between the two was calculated. The in vivo clot-to-blood ratio was surprisingly high (126+/−52, Table 6) and significantly above the ratio described in the closest prior art (US 2007/0189970 A1).

(637) TABLE-US-00043 TABLE 6 Clot-to-blood ratios in vivo (Cynomolgus monkey) Clot Blood [cpm/mg] [cpm/mg] Clot/Blood 25578 130 196 7204 100 72 9545 100 96 9011 90 100 14801 90 164 mean 126 sd 52

(638) Table 6 shows the compound concentration in thrombus (clot) and blood and the resulting in vivo clot-to-blood ratio determined from 5 thrombi out of the monkey imaging experiments described above. It was found to be surprisingly high, and significantly higher than showed in the closest prior art (US 2007/0189970 A1)

CONCLUSION

(639) The compound described in example 40 shows surprisingly high accumulation even in slightest venous and arterial thrombi in monkeys. There was almost no background in any surrounding tissue or organ in any of the investigated monkeys. The compound almost completely remains within the thrombus over a long time (60 minutes were shown). In contrast to the closest prior art (US 2007/0189970 A1) the dose given in the here described experiments was almost 50-fold lower and the in vivo clot-to-blood ratio was significantly higher at the same time.